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Abstract 
Hepatitis (HCV) is a communicable disease that impacts many Americans. The 
scholarly literature lacked the knowledge pertaining to the relationships between poverty 
and HCV diagnosis and prescription for HCV medication. The purpose of the study was 
to measure the magnitude and statistical significance of these relationships, as modeled 
by the health belief model and public health surveillance and action framework.  
Specifically, the study was designed to determine whether there is a statistically 
significant relationship between living below the poverty line and being diagnosed with 
HCV, as well as living being below the poverty line and being prescribed HCV 
medication. A total of 78 records of HCV-positive individuals from the National Health 
and Nutrition Examination Survey dataset were evaluated by applying the statistical 
procedure of odds ratio (OR) analysis. The results of the analysis revealed  that (a) there 
was not a statistically significant relationship between being below the poverty line and 
being diagnosed with HCV, OR = 0.99 (SE = 0.38, z = -0.03, p = .974); and (b) there was 
not a statistically significant relationship between being below the poverty line and being 
prescribed HCV medications, OR = 0.32 (SE = 0.55, z = -0.66, p = .507). Numerous 
recommendations for improving measurements of the relationship between poverty and 
HCV are provided. This study may promote positive social change by indicating the 
importance of poverty as an agenda item for public health policy and practice.  
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Chapter 1: Introduction 
Background of the Problem 
The hepatitis C virus (HCV) is a blood-borne pathogen that is rapidly emerging as 
a major public health concern (Valdiserri et al., 2014).  HCV, which affects millions of 
people, damages the liver. By the time HCV carriers notice symptoms, the disease may 
have matured to an advanced stage of liver complications (such as liver damage or liver 
cancer) that can lead to death.  Research shows that HCV risk is highest among baby 
boomers, with the prevalence of HCV in this population of Americans being 1 out of 30, 
or 3.3% (Valdisseri et al., 2014).  Globally, over 100 million people are living with HCV, 
and 90% of cases of HCV worldwide exist in communities that are plagued with low 
socioeconomic conditions (Lanini, Esterbrook, Zumla, & Lippolito, 2016; Solomon et al., 
2015).  Today, roughly 3.5 million people are living with HCV in the United States 
(National Institute of Drug Abuse [NIDA], 2018). HCV is one of the major causes of 
premature mortality in the United States (Falade-Nwulia et al., 2016). 
Marginalized groups, or communities with low socioeconomic status are 
disproportionately more likely to struggle with homelessness, mental illness, opioid drug 
use, injection drug use, or other substance issues (Solomon et al., 2015).  The poor often 
lack access to insurance, affordable clinical treatment, and prevention programs (Falade-
Nwulia et al., 2016; Solomon et al., 2015).  Poverty alone appears to be a major risk 
factor for HCV.  Without testing, linkage to care, and treatment effectiveness, poor 
carriers of HCV can unknowingly spread the disease to others through various risky acts, 
such as unprotected sexual intercourse or exposure through unclean needle sharing or use 
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(Falade-Nwulia et al., 2016).  The focus of this quantitative study is on quantifying the 
incidence of HCV in the United States as a function of poverty, controlling for 
demographics. 
There are numerous reasons to believe that HCV is disproportionately more 
prevalent among the poor, among whom it constitutes a major public health problem.  
One of the main reasons that HCV is a public health problem among the poor is that it 
can be transferred by multiple methods, such as blood and saliva exchange.  Fluid 
exchange may occur through drug use, unprotected sex with multiple partners, and 
living in poorly kept homeless hostels and shelters (Beijer, Wolf, & Fazel, 2012; 
Gelberg et al., 2012; Neal & Stevenson, 2012; Stein et al., 2012). The problem might be 
more significant than it appears, because, as Chak et al. (2011) and Edlin et al. (2015) 
stated, almost 1.9 million people infected with hepatitis were not included in national 
statistics, due to being members of marginalized groups such as the mentally ill, 
convicts, substance abusers, and those who are homeless.  Research suggests that 
proportionally few homeless individuals, mentally ill people, and drug users know that 
they have contracted hepatitis (Hermanstyne, Bangsberg, Hennessey, Weinbaum, & 
Hahn, 2012; Notaro et al., 2012; Nyamthi et al., 2013). Those with education and 
knowledge of hepatitis among marginalized groups are less likely to be infected; 
however, the number of those with knowledge of the disease is small (Himelhoch et al., 
2011; Strehlow, 2012). Himelhoch et al. (2011) acknowledged that further studies need 
to be conducted regarding levels of access to healthcare and education for marginalized 
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groups who have a high susceptibility to hepatitis; such studies could influence health 
policy toward providing expanded access to health care for the poor (Notaro et al., 2013).  
Statement of the Problem 
HCV, a contagious and potentially deadly disease, has historically hurt 
many marginalized members of society, such as the homeless, mentally ill, substance 
abusers/users, and ex-convicts, who are at high risk for infection, and who might lack 
access to adequate medical treatment (Centers for Disease Control and Prevention 
[CDC], 2015; Chak et al., 2011).  The problem addressed in the study was twofold: (a) 
lack of knowledge as to the odds-based relationships between HCV risk (in terms of 
incidence, diagnosis, disclosure, and treatment) as a function of poverty, and (b) lack of 
synthesized explanations of how and why HCV appears to function differentially in terms 
of incidence, diagnosis, disclosure, and treatment among the poor. The second problem 
was addressed in the literature review, whereas the first problem was addressed by the 
quantitative research design of the study.  
Purpose of the Study 
The purpose of the study was to apply statistical analysis to data from the 
National Health and Nutrition Examination Survey (NHANES) to (a) estimate the odds-
based relationships between HCV risk (in terms of diagnosis and treatment) as a function 
of poverty, and (b) provide synthesized explanations of how and why HCV appears to 
function differentially in terms of diagnosis and treatment among the poor.  These 
purposes were achieved through the quantitative approach described and defended in 
Chapter 3.  
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Research Questions and Hypotheses 
The research questions and hypotheses of the study were as follows.  The means 
of answering these research questions are discussed and justified in Chapter 3.  
RQ1:  Is there a statistically significant relationship between being below the poverty 
line and being diagnosed with HCV? 
H10: The odds ratio (OR) of having HCV as a function of poverty = 1. 
H1A: The OR of having HCV as a function of poverty ≠ 1. 
RQ2:  Is there a statistically significant relationship between being below the poverty 
line and being prescribed HCV medications?  
H20: The OR of being prescribed HCV medications as a function of poverty = 1. 
H2A: The OR of being prescribed HCV medications as a function of poverty ≠ 1.  
Theoretical Frameworks 
The two theoretical frameworks of the study were the health belief model (HBM) 
and public health surveillance and action framework (PHSA).  The HBM suggests that 
the poor might incur HCV at disproportionate rates because of their differential beliefs 
about disease transmission, management, and cure, thus providing underpinnings for the 
two quantitative research questions of the study.  The PHSA suggests that the public 
health of the poor might not rise to the full attention of the policy establishment, thus 
providing theoretical underpinnings for the research questions of the study. 
Definition of Terms 
Centers for Disease Control and Prevention (CDC): The U.S. agency charged 
with tracking and investigating public health trends.  A part of the U.S. Public Health 
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Services (PHS) under the Department of Health and Human Services (HHS), the CDC is 
based in Atlanta, Georgia. It publishes key health information, including weekly data on 
all deaths and diseases reported in the United States, and travelers’ health advisories.  The 
CDC also fields special rapid-response teams to halt epidemic diseases (Al Knawy, 
2015). 
Cirrhosis: Liver disease characterized by irreversible scarring.  Alcohol and viral 
hepatitis, including both hepatitis B and hepatitis C, are among the many causes of 
cirrhosis. Cirrhosis can cause yellowing of the skin (jaundice), itching, and fatigue. 
Diagnosis is suggested by physical examination and blood tests, and it can be confirmed 
by liver biopsy.  Complications of cirrhosis include mental confusion, coma, fluid 
accumulation (ascites), internal bleeding, and kidney failure.  Treatment is designed to 
limit any further damage to the liver and to prevent complications.  Liver transplantation 
is becoming an important option for patients with advanced cirrhosis (Al Knawy, 2015). 
Genotype: The genetic constitution (genome) of a cell, an individual, or an 
organism. The genotype is distinct from the expressed features, or phenotype, of the cell, 
individual, or organism.  The genotype of a person is that person’s genetic makeup.  It 
can pertain to all genes or to a specific gene (Al Knawy, 2015). 
HCV diagnosis: HCV diagnosis takes place when a physician interprets laboratory 
evidence as indicating that an individual has HCV (Al Knawy, 2015).  
HCV treatment: Administration of pharmacological treatment for HCV (Al 
Knawy, 2015). 
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Hepatitis C: Inflammation of the liver due to the hepatitis C virus (HCV), which 
is usually spread via rare blood transfusion, hemodialysis, or needle sticks (Al Knawy, 
2015). The damage to the liver that hepatitis C does, can lead to cirrhosis and its 
complications, as well as cancer.  Transmission of the virus by sexual contact is rare.  At 
least half of hepatitis C patients develop chronic hepatitis C infection. Diagnosis is made 
by blood test.  Treatment and probably cure occur via antiviral drugs, which are effective 
in over 90% of patients.  Chronic hepatitis C was once frequently treated with 
injectable interferon, in combination with antiviral oral medications, but now it is most 
often treated with oral antivirals alone.  There is no vaccine for hepatitis C (previously 
known as non-A, non-B hepatitis). 
Poverty line: An income level below which an individual is considered by the 
U.S. government to be in poverty (Al Knawy, 2015).  
Significance of the Study 
There appears to be substantial agreement in the literature that HCV is 
disproportionately found among the poor.  There is a gap in the literature on quantifying 
HCV (in terms of its diagnosis and treatment) as a function of poverty.  The main 
significance of the current study lies in its ability to analyze NHANES data in order to 
calculate the odds of HCV diagnosis and treatment as functions of poverty, leading to 
more reliable and objective assessments of how HCV impacts the poor.  The secondary 
significance of the study lies in its ability to apply a systematic literature review to better 
understand how and why HCV disproportionately impacts the poor.   
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At-risk populations such as the mentally ill and homeless have an extremely high 
risk of hepatitis contraction (Himelhoch et al., 2011; Stein et al., 2012). Nyamathi et al. 
(2013) found that among groups such as the homeless, mentally ill, and substance 
abusers, those educated on hepatitis were less likely to contract it.  There is an 
established call to increase the funding and number of free clinics to help diagnose and 
treat hepatitis among these groups (Notaro et al., 2013; Nyamathi et al., 2012; Nyamathi 
et al., 2013).  While researchers have evidence that accessible health care and education 
do help those with hepatitis infections, there has been minimal investigation on the 
quantitative relationship between HCV (in terms of factors such as diagnosis, disclosure, 
prevalence, and treatment) and poverty (Nyamthi et al., 2012).  As the hepatitis threat 
continues to grow across the United States, especially within underprivileged 
communities, it is important to find policy options that maximize success (Edlin, 2015).  
Better understanding HCV among the poor can help to refine and target such options.   
Conclusion 
The purpose of Chapter 1 was to introduce the problem of a lack of knowledge 
about HCV diagnosis and treatment as functions of poverty.  An odds ratio (OR) 
approach was suggested as a means of addressing this knowledge gap, and background 
information about HCV was provided.  The remainder of the study has been structured as 
follows.  Chapter 2 consists of the review of literature. Chapter 3 consists of the study 
methodology and design.  Chapter 4 contains the findings. Chapter 5 consists of the 
conclusion.  
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Chapter 2:  Literature Review 
Introduction 
The purpose of the study was to apply statistical analysis to data from NHANES 
to (a) estimate the odds-based relationships between HCV risk (in terms of diagnosis and 
treatment) as a function of poverty, and (b) provide synthesized explanations of how and 
why HCV appears to function differentially for the poor. The purpose of the literature 
review is to address the second purpose through a discussion of the theoretical framework 
and empirical studies that address the issues of HCV prevalence and treatment among the 
poor.  
Literature Search Strategy 
A literature review was conducted in an effort to evaluate the research for its 
relevance to this study.  A variety of databases including EBSCO Host, Academic Search 
Complete, ProQuest, Google Scholar, and Research Gate were accessed.  Key words and 
combination of key words were used to find relevant studies.  These terms included, but 
were not limited to, hepatitis C, homelessness, injection drug users, and access to care.  
Overall, roughly 31 articles met inclusion criteria for the review.  
Background of HCV 
HCV is a contagious and potentially deadly blood-borne and sexually transmitted 
virus that is a public health problem not only in the United States, but worldwide 
(Valdiserri et al., 2014). Although the prevalence of HCV appears highest among 
marginalized individuals in urban communities, it has become a growing problem 
worldwide in suburban and rural communities (Solomon et al., 2015).  HCV is 
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preventable.  Over 50% of the individuals infected with the disease simply are not aware 
that they have it.  In other words, they have not been tested, evaluated, diagnosed, or 
treated for HCV.  Just knowing about the disease is not enough; those infected must be 
treated.  Without testing, linkage to care, and effective treatment, people with HCV can 
unknowingly spread the disease to others through various risky acts such as unprotected 
sexual intercourse or exposure through unclean needle sharing or use (Falade-Nwulia et 
al., 2016).  
Between 2013 and 2014, Falade-Nwulia et al. (2016) conducted a 9-month study 
of roughly 2,681 HCV-positive individuals within the Baltimore, Maryland metropolitan 
area. In that study, they tested the impact of an integrated care delivery model in a public 
health clinic on the identification and timely treatment of patients at risk of having been 
exposed to HCV.  Falade-Nwulia et al. found that an integrated care delivery approach 
within a public health setting was very effective, especially when coupled with a 
structured screening, testing, and referral-to-treatment program for at-risk populations.  In 
other words, an integrated care delivery program is more likely to have the needed 
structure and clinical protocols to identify patients with HCV infection and get them 
timely access to the necessary treatment, as well as follow-up counseling regarding 
transmission and harm reduction (Falade-Nwulia et al., 2016).   
Valdiserri et al. (2014), in a recent study, estimated that approximately 2.9 million 
people were living with HCV in the United States, and many were not even aware that 
they were infected with the virus.  High-risk behaviors and injectable drug use are the 
primary contributing factors in HCV infection for adults and young people who inject 
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drugs (PWID) in the United States of America (Artenie et al., 2015; Lanini et al., 2016; 
Page, Morris, Hahn, Maher, & Prins, 2013).  In addition, PWID experience higher 
morbidity and mortality rates nationally (Valdiserri et al., 2014).  Lanini et al. (2016) and 
Solomon et al. (2015) agreed that early diagnosis and timely clinical intervention are keys 
to successfully addressing the HCV epidemic in America, especially in marginalized 
communities infested with drug abuse.  Without the necessary clinical diagnosis and 
treatment for those infected, these communities may experience remarkable increases in 
the incidence of HCV, along with rapidly growing premature death or mortality rates 
(Solomon et al., 2015).  Recent improvements in HCV medications have given rise to the 
possibility of actually curing HCV in infected individuals (Lanini et al., 2016).  Solomon 
et al. recommended the development of training programs from effective scholarly 
research and lessons learned, that could be used to improve education and increase 
awareness of HCV prevention and treatment options for targeted communities across the 
nation.  In other words, a well-developed, evidence-based public health program can be 
used to teach individuals across the United States more effective ways to prevent or 
reduce the transmission of HCV.  This effort may yield remarkable dividends nationally 
as well as worldwide, by enhancing the survivability of those suffering with HCV as well 
as helping to reduce the progression of the HCV and HIV diseases globally (Solomon et 
al., 2015).    
Theoretical Framework 
This research was supported by two theories: the HBM and the PHSA.   
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Health Belief Model (HBM) 
The HBM is a type of health behavior theory (HBT).  Livi, Zeri, and Baroni 
(2017) argued that for more than 40 years, scholars have used the HBM to understand 
and explain the degree to which determinants influence and modify health-related 
behaviors.  The HBM contains some of the major psychological predictors of health-
related behaviors.  It is composed of four sections: perceived susceptibility, perceived 
severity, perceived barriers, and perceived benefits (Skinner et al., 2015).  These four 
concepts can help determine why and when an individual will seek a remedy for a 
disease.  In other words, these four concepts can be combined into the two main 
components of HBM: behavioral evaluation and threat perception.  Behavioral 
evaluation focuses on the perceived benefit gained and the associated barriers 
experienced, while threat perception addresses perceived susceptibility and anticipated 
severity.  Vulnerability to a health illness tends to drive the perception of susceptibility, 
whereas the perceived consequences of a health illness tend to drive anticipated severity 
(Livi et al., 2017).  In terms of RQ1, HBT predicts that HCV will be diagnosed at a 
greater rate among the poor, because the poor will have disproportionately indulged in 
health behaviors likely to result in HCV.  
Public Health Surveillance and Action (PHSA) Framework  
The PHSA is a theory designed to explain the motivations behind government and 
the public sector taking steps to safeguard the general public from health crises (Kohl et 
al., 2012). The PHSA suggests that, in general, governments are highly motivated to 
make the diagnosis and treatment of infectious diseases simple, even if people who are 
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vectors for such diseases are uninsured or otherwise difficult to monitor (Kohl et al., 
2012).  In the context of this study, the PHSA was applied to understand the decision-
making process of healthcare providers. The PHSA predicts that a country with a robust 
public health system, such as the United States, will take meaningful action to curtail or 
manage infectious diseases in all segments of the population. Therefore, in relation to 
RQ2, the PHSA predicts that poor people will be treated for HCV at least as frequently as 
people who are not poor.  
Prevalence of HCV 
In their review of epidemiological studies, Chak et al. (2011) obtained data from a 
variety of databases, including those of Medicare and Medicaid and the Department of 
Corrections, to arrive at the true prevalence of HCV in the United States. The results of 
the review indicated that there were underestimations in terms of the number of veterans 
with a positive diagnosis of HCV.  Chak et al. and Edlin et al. (2015) stated that almost 
1.9 million people infected with hepatitis were left out of national statistics, due to being 
members of marginalized groups such as the mentally ill, convicts, substance abusers, 
and those who are homeless. 
Edlin and Winkelstein (2014) argued that, based on reported statistics of the 
prevalence of HCV, it is feasible to eradicate HCV in high-income countries such as the 
United States.  Eradicating HCV is not an easy task and requires increased efforts in 
terms of screening, prevention, treatment, policy, research, and advocacy.  Edlin and 
Winkelstein postulated that all individuals should be tested for HCV, and health services 
should be prepared to provide antiviral drugs for all who are infected.  Further, prices for 
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these treatments should be affordable.  Services for those marginalized groups who are 
disproportionately infected with HCV should be made available, and the legal barriers to 
hepatitis C prevention should be removed.   
HCV infection is a concern among marginalized groups due to the multiple 
methods by which the virus can be transmitted, such as through blood, saliva, drug use, 
unprotected sex, and poorly kept abodes and shelters.  In a systematic review and meta-
analysis, Beijer, Wolf, and Fazel (2012) reviewed the literature on the prevalence of 
HCV, tuberculosis (TB), and HIV in the homeless population.  Beijer et al. examined 
research published between January 1981 and January 2012.  Two criteria were set for 
inclusion in the review.  First, the study had to include a sample of individuals considered 
homeless, living in shelters or institutions, or living in rough conditions not due to war or 
natural disasters.  The second criterion was the inclusion of data on the prevalence of TB, 
HIV, and HCV, diagnosed through chest x-ray, blood test, or self-report questionnaires.   
There were 43 studies that were included in the review and meta-analyses, 
representing 59,736 individuals.  The review indicated that HCV was the most prevalent 
of the three diseases among the homeless population.  Tuberculosis ranked the lowest of 
the three diseases.  Prevalence ranged from .2% to 7% for TB, 3.9% to 36% for HPV, and 
.3% to 21% for HIV.   
Beijer et al. (2012) also identified the need for more studies to examine local 
populations in order to inform best practices for public health and service measures.  The 
implications of their review was that those in charge of planning and development 
services should consider as a viable alternative the management of infectious diseases in 
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homeless populations.  Beijer et al. further suggested universal screening of homeless 
individuals as a consideration for reducing the prevalence of these three infectious 
diseases. 
While some research has been conducted on specific groups of HCV victims, 
further research needs to be performed to determine the challenges or gaps for those who 
may not have access to medical treatment and are left unaware of the disease (Gelberg et 
al., 2012).  Neal and Stevenson (2012) addressed this gap in their qualitative study.  Neal 
and Stevenson gathered information using semi-structured interviews on the needs of 
homeless drug users temporarily staying in shelters or hostels.  The overarching theme 
among the 40 participants interviewed in this study was the slow removal of blood and 
other bodily fluids in hostels and shelters.  The presence of blood poses a risk of 
transmission, because blood infected with the hepatitis virus can survive for several 
weeks outside the body.  Dried and spilt blood from risky injection in hostels and shelters 
may help to explain the high levels of hepatitis C virus among homeless individuals. 
Strehlow et al. (2012) examined the prevalence of HCV among the homeless in 
primary care settings.  The researchers identified the distribution and risk factors for 
homeless adults with a diagnosis of HCV who were using eight nationwide Health Care 
for the Homeless (HCH) clinics.  Data were obtained using structured interviews, chart 
reviews, and blood draws.  Within the homeless population explored, the overall 
prevalence of HCV-antibody positivity was 31.0%.  However, when the participants were 
subdivided into injection drug users and non-injection drug users, it was conclusive that 
the prevalence of HCV-antibody positivity was 70.0% among injection drug users and 
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15.5% among non-injectors.  Over 50 of the participants who tested positive for HCV 
were unaware of their health status at the time the initial interviews were conducted. 
Identified risk factors for HCV among injectors were prison and injection drug use.  For 
non-injectors, the risk factors were tattoos and prison.  
Hermanstyne et al. (2012) examined the relationship between HCV and 
implements used for non-injection drug use.  A large sample of homeless individuals in 
San Francisco was recruited for this study.  The researchers examined implements used 
for smoking or snorting drugs and HCV.  Sociodemographic variables were controlled.  
They also assessed the relationship between HCV, sexual history, substance abuse, 
incarceration history, and presence of tattoos or piercings.  The results suggested that 
there is no significant relationship between HCV and non-injection implements for drug 
use.  In other words, these implements were not a risk factor for HCV status.   
In another study on the vulnerable homeless population, Stein et al. (2012) 
assessed the influence of hepatitis C infection on the homeless population in the area 
known as “Skid Row” in Los Angeles, California using the Gelberg-Andersen behavioral 
model for vulnerable populations.  This model is appropriate in predicting hepatitis B and 
C infection positivity, and utilization of health services in homeless individuals.  The 
sample included 534 homeless adults.  These participants were tested for hepatitis B and 
C, interviewed on their utilization of health services over the past 12 months, and their 
awareness of a positive diagnosis for hepatitis B and C.  Using structural equation 
modeling, the researchers concluded that 72% of hepatitis B and C cases were predicted 
by older age, risky sexual behavior, injection drug use, and alcohol use.  However, 
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emergency services were used far less by those diagnosed with positive hepatitis B or C.  
This study highlights the importance of more intensive screening of the homeless 
population for hepatitis B and C given the high incidence of the diseases and lack of 
awareness of the diseases among this vulnerable population.  
Awareness of Infection Status 
Himelhoch et al. (2011), Notaro et al. (2013) and Nyamathi et al. (2012) agreed 
that among marginalized populations studied with HCV, roughly a quarter of the people 
who were homeless, mentally ill, and people who injected drugs (PWID) knew that they 
had contracted hepatitis.  Disparities in access may lead to inadequate HCV awareness 
and detection, as well as gaps in HCV treatment, resulting in increased health costs, poor 
outcomes, and worsening health.  When left untreated or undiagnosed, HCV can easily be 
spread, with a resultant increase in emergency room visits, creating a larger health risk 
and costs for the general populace (Nyamathi et al., 2013). 
Nyamathi et al. (2012) examined the relationship between knowledge of hepatitis 
and HIV among gay and bisexual homeless individuals living in Hollywood, California.  
A sample of 267 gay and bisexual (G/B) men participated in the study.  The age range of 
participants was between 18 and 39 years old.  The goal of this longitudinal study was to 
reduce the use of drugs and improve knowledge of HPC and HIV in a community center.  
Results of regression modeling revealed that education on HIV/AIDS previously 
delivered to the G/B men was related to higher levels of knowledge about HIV/AIDS. In 
this study, higher levels of knowledge about hepatitis were related to more moderate drug 
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use.  This study highlights the need for accessing testing early and using teaching 
strategies to reduce harm.   
Himelhoch et al. (2011) found that marginalized groups (i.e., PWID) that were 
well educated and had a strong knowledge of HCV were less likely to be infected.  
However, absent the education, a smaller number of the group expressed knowledge of 
the disease and were more likely to be infected (Himelhoch et al., 2011). 
Himelhoch et al. (2011) examined screening and testing rates for HCV, HIV, and 
co-occurring substance use disorders in a sample of individuals with mental illness and 
substance abuse.  The sample included 53 participants diagnosed with a serious mental 
illness and substance abuse disorder.  The participants were tested for HCV and HIV.  
Within this sample, 25% tested positive for HCV, and 6% tested positive for HIV.  The 
majority of the sample revealed a history of risky sexual behaviors and engaging in 
unprotected sex.  Results of this study indicated that individuals diagnosed with HCV are 
more likely to have engaged in unsafe sex, have injected drugs, and have a sexually 
transmitted infection.   
Treatment of HCV 
Shiffman and Benhamou (2015) posited that effective treatments have been 
available for chronic HCV for upwards of two decades.  In addition, there has been 
effective treatment for HCV and associated diseases, such as Recombinant ImmunoBlot 
Assay (RIBA) virus testing and Interferon (IFN) treatment.  RIBA testing (e.g., enzyme 
immunoassay confirmatory testing) or HCV antibody testing and IFN treatment are 
current practices for properly assessing suspect HCV in at-risk populations (Shiffman & 
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Benhamou, 2015, p. 72).  However, quite intriguing and relevant to understanding the 
risks of HCV, are the need for improved access.  Shiffman and Benhaumou also 
emphasized that “pegylated interferon alpha (PEG-IFN) and RBV reduce HCV RNA to 
undetectable levels in approximately 66% of patients with HCV genotype 1 (HCV-1) and 
over 90% of those with genotypes 2 and 3 (HCV-2,3)” (p. 72).  They argued that a 
sustained virological response (SVR) takes place in about 40%, 80%, and 70% of these 
patients, respectively, referring to the different types of patients considered in their study 
(p. 72).  They also suggested that the efficacy of the treatment could vary according to 
“genetic susceptibility to IFN” (p. 72), but the primary observation was that long term 
follow up by genotype would be needed on participants in the study who had achieved 
SVR, before claiming the current testing and treatment resulted in 100% cure of HCV (p. 
72). 
The central issue is that, with a cure available and generally successful, it is a 
particularly poor reflection when the treatment success potential is so significant but a 
relatively high majority of populations at-risk for HCV decides to shy away from 
treatment access.  Arguably, it becomes a matter of increasingly serious concern. 
Vulnerable populations tend to be marginalized and allowed to remain vulnerable; even 
in the face of a condition that can cause premature death from liver damage (i.e., HCV) 
and can occur alongside other more serious conditions; each of which are basically 
treatable.  
Urban cities may be ill-equipped to handle a large outbreak among the most 
marginalized members of society without further knowledge of the specific disparities 
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within populations at-risk for HCV, the demographics, and their ability to access 
effective prevention, detection and treatment programs (Nyamathi et al., 2013; Stein et 
al., 2012; Stehlow et al., 2012).  Himelhoch et al. (2011) acknowledged that further 
studies need to be conducted regarding levels of access and education for marginalized 
groups (i.e., drug users) who have a high susceptibility to hepatitis. 
Access to Healthcare 
Notaro et al., (2013) examined the status of health among a sample of homeless 
individuals, and their use of free clinics.  The prevalence of many diseases including 
HCV was compared among the homeless population.  The data for this study were 
collected from medical records over a five-year period.  The health conditions of the 
homeless population using the free clinic were compared to the users of the general 
clinic.  The results indicated similarities between the groups.  However, the homeless 
group had significantly more cases of hepatitis, anxiety, bipolar disorder, and 
tuberculosis, compared to the general clinic group.  This study illustrates how the 
homeless population who use free clinics have lower levels of health, compared to the 
general population.  Notaro et al. (2013) found that access to health care for the mentally 
ill needs to be increased; doing so could help detect hepatitis infections.   
Understanding the reasons why the injection drug use (IDU) community does not 
currently access appropriate treatments for HCV is no mean feat.  There are many factors 
to consider, and there is much at stake.  Existing studies demonstrate that there are 
several special interest issues.., people who inject drugs (PWID) being one of them, that 
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require attention because of issues such as the associated costs and the commonality of 
HCV and the lack of treatment access at present. 
One of the most substantial issues for PWID with HCV is treatment management 
and completion.  In some cases, patients do not necessarily make a decision to pursue 
treatment when it is available (NIDA, 2018, May 29)  Part of the issue in this instance is 
that most drugs used by PWID (such as cocaine, DMT, heroin, ketamine, 
methamphetamine, phencyclidine [PCP], etc.) tend to alter a person’s thinking and 
judgment, which leads to health risks that include addiction, drugged driving and 
infectious diseases such as HCV and HIV (NIDA, 2018, May 29).   
Roux et al. (2013) considered HCV infection in non-treatment-seeking heroin 
users, and specifically investigated what they call the burden of cocaine injection.  Their 
findings suggest that in heroin-dependent individuals, control of the HIV epidemic has 
been achieved in countries where opioid maintenance treatment (OMT) and needle 
exchange programs (NEP) are available and promoted as primary treatment options.  
Roux et al. (2013) also insist that, despite what they call routes of contamination 
for both viruses, the instances of HCV infection remain high.  Roux et al. stated their 
research objective as the identification of the prevalence of HCV, and an assessment of 
the correlation of being HCV-positive in a sample of individuals who have otherwise left 
treatment for heroin.  Notably, their findings affirm that the risk of HCV-infection 
through intravenous drug use, with cocaine particularly, is extremely high. The results 
stress the significance of rethinking interventions to undermine the risk of HCV 
infections in the vulnerable population (p. 613).  Roux et al. insisted that their research 
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provided important insights for public health decision makers and advice for the 
implementation of adequate programs that will ensure access and treatment follow-
through among the vulnerable population of drug users (p. 617).  This will likely be the 
case with the current study. 
Martin et al., (2013) stressed that although it is possible to reduce HCV in PWID, 
a substantial reduction cannot be expected to be accomplished solely with harm reduction 
interventions, such as a needle exchange program.  Slow uptake, higher baseline 
prevalence, or shorter average injecting duration appears to remain the greatest 
challenges to significantly reducing chronic HCV prevalence, even in countries where 
new, effective and tolerable interferon-free direct acting antiviral (DAA) treatments are 
available, such as Edinburgh, UK, Melbourne, Australia and Vancouver, Canada.  Higher 
uptakes and lower baseline prevalence could make a major difference in treatment 
modalities for HCV, however, treatment costs remain a limiting factor.  Based on the 
current HCV medications costs, it takes millions in US dollars to halve the HCV 
prevalence in target populations of PWID (Martin et al., 2013).   
Bruggmann (2013) agreed that barriers to access remain, a problem especially in 
drug dependency settings.  Lack of understanding or information, a low prioritization 
among patients, and a lack of treatment considerations based on costs a few of many 
challenges facing organizations seeking to scale-up of treatment among IDU.  It is 
impossible without programs to improve the HCV and addiction literacy, and break down 
the barriers to treatment access, without addressing the discrimination and stigmatization 
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among physicians who have the appropriate training to effective treat PWID with a 
diagnosis of HCV.   
Asher, Lum, and Page (2012) reflected on the suitability for acute HCV treatment 
among a more specific population: active young injection drug users.  Asher et al.’s 
support that the treatment for acute HCV has much better outcomes than treatment for 
chronic infections, which perhaps pertains to the idea of reinfection that is nonetheless 
common in most groups.  Asher et al. suggested that the acute period for the treatment of 
HCV is brief and, thus, creates several challenges for young PWID such as limited access 
to clinics and completion of treatment. However, the acute period tends to provide the 
best opportunity to treat young PWID (16).  In their case study, Asher et al. (2012) 
considered five acutely-infected contributors and reported on their daily drug use at 
baseline (p. 16).  All five acutely-infected contributors that had access to primary care 
decreased their drug use (p. 26) although none received treatment for their active 
infection; one was treated within 12 months of infection" (p. 16). Again, Asher et al. 
insisted that research demonstrated that HCV infection treated during the acute phase is 
remarkably more effective at achieving a positive result" (p. 16) compared to those with a 
chronic infection.  Asher et al. noted that there are substantial implications for this, not 
least to do with potential policy revisions regarding acute versus chronic infection.  The 
way in which this present study can contribute to this is again by showing the relevance 
of access and considering whether one of the more substantial issues in defining the 
successful outcome of different treatment patterns is not simply access. 
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Many studies have suggested a disparity between drug users and non-drug users 
in relation to treatment for HCV.  What is clear is that drug users are often perceived 
quite negatively, and willing participants in treatment programs may not always have 
proper access to the treatment they need, even when they are very willing to pursue 
treatment.  It might also be proposed that the issues with treatment decision making and 
even condition awareness amongst PWID could come down to general access to 
treatment.  If they are not provided access to treatment that is catered to their condition as 
drug users, which is arguably a co-occurring condition, then is it viable to say that they 
even have access to the treatment that they need.  This present study again helps to tease 
out that problem and will examine the social implications of this possibility.  
Asher et al. (2012) conducted a 20 months study from January 2007 to September 
2008 that involved six individuals (2 females and 4 males) with acute HCV that were 
enrolled in a treatment program.  The participant ages ranged from 20 to 31 years of age.  
The age demographics included five Caucasian participants and one African American 
participant. All participants indicated daily drug use.  The drugs of choice were 
methamphetamine, heroin, and crack cocaine.   
The findings notably confirmed that the treatment candidacy for acute HCV 
infection pertains not only to physiological factors that can indicate treatment readiness, 
including "evidence of virus in the blood and no contraindications to IFN therapy" (p. 
26), but also psychosocial factors.  These factors, as well as “alcohol use, housing status, 
lack of social support, mental illness, access to health care, and continued drug use may 
significantly impact treatment readiness” (p. 26). Asher et al. (2012) conclude that “even 
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when this population willingly engages in support and education around acute HCV, 
becoming ‘good’ candidates is an intensive process for both patients and their care 
providers” (p. 26).   
Asher et al. observed that many active injectors are homeless, lack primary care, 
and tend to have uncontrolled or untreated mental health issues (p. 26). The expectation 
of many treatment programs that they are then expected to alter their lifestyle very 
dramatically and in a short space of time is quite unrealistic, particularly when the actual 
supports of the program do not address many of the psychosocial issues that are 
undermining their quality of life to begin with.  
Asher et al. (2012) noted that the advantage of the program used as a focus for 
their research in working with PWID was that it was based on a small patient population. 
The study was also supported by a nurse who had the means to provide specific care, to 
make referrals to meet the patients’ various other needs, and to advocate for further help 
as and when needed.  Asher et al. (2012) suggested that the importance of challenging 
individual, clinician, social, and psychological barriers could hardly be exaggerated for 
the IDU populations in question, , and the advantage of providing individualized care and 
further support groups targeting the range of issues contributing to the individual 
condition were substantial.   
Asher et al. (2012) also insisted that although the relatively short timeframe for 
the acute period, besetted by the multiple co-occurring disorders and social issues 
presented by each patient, fostered significant challenges  (p. 26), the relatively short 
timeframe compared to cases of chronic HCV should still be regarded as significant and 
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impactful.  The need to provide supports for individual, clinician, social, and 
psychological barriers is hard to overemphasize, particularly based on these findings.  
However, what also appears clear is that many studies and indeed many treatment 
programs that base their work on studies do not yet acknowledge the need for this range 
of support and the co-treatment and management of the various issues that IDU tend to 
face that impact their lifestyle choices and opportunities.  
Many studies have suggested a disparity between drug users and non-drug users 
in relation to treatment for HCV.  What is clear is that drug users are often perceived 
quite negatively, and willing participants in treatment programs may not always have 
proper access to the treatment they need, even when they are very willing to pursue 
treatment.  It might also be proposed that the issues with treatment decision making and 
even condition awareness amongst PWID could come down to general access to 
treatment.  If the PWID hey are not provided access to treatment that is catered to their 
condition as drug users (which is arguably a co-occurring condition), then is it untrue to 
say that they have access to the treatment that they need.  This present study again helps 
to tease out that problem and will examine the social implications of this possibility.  
Summary, and Gaps in the Literature 
Estimates indicate more than 3.5 million people in the United States are living 
with HCV (NIDA, 2018). This study examined access to health care and its influences on 
the number of acute HCV infections among PWID.  Injection drug usage (IDU) is 
recognized as the primary route of HCV contraction (NIDA, 2018), suggesting that one 
of the reasons why HCV continues to affect marginalized members so dramatically is that 
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IDU users represent one of the most vulnerable groups and are prone to infection.  A 
literature review thoroughly evaluated the research for its relevance to this study.  
Selected articles related to disparities in access and the influence on treatment for HCV in 
PWID.  From the literature review, it was concluded that total elimination of HCV is 
possible as major advancements have been made with the development of sensitive 
diagnostics tests and very effective direct-acting antiviral (DAA) agents that are unique in 
delivering sustained viral response (SVR) in over 95% of patients who are diagnosed 
early and treated.  However, the key to effectively eliminating the spread of HCV in the 
United States to expand or put prevention interventions into practice such as the needle 
exchange and clean syringe programs, opioid substitution therapies and behavioral health 
services (Sabb et al., 2018).  In addition, improved health promotion, community 
awareness, needle sharing, other harm reduction strategies, and adequate public health 
funding for programs like the British Columbia, Canada implement implemented 
between 1996 and 2015 (Olding et al., 2017).  In terms of risks and vulnerabilities for 
HCV, rural areas tend to have a very high number of documented PWID (Van Handel et 
al., 2016). Further, a minimal number of homeless, mentally ill, and PWID know that 
they have contracted hepatitis. The expanding epidemic of opioid abuse and injection 
drug use (IDU) have intersected the growth of HCV infections in communities across the 
nation; especially in non-urban communities (Van Handel et al., 2016).  Zibbell et al. 
(2018) concurred in their study that the rapid increase in acute HCV infection in the 
United States was strongly correlated to the increases in IDU or PWID and the growing 
opioid epidemic that plagues the nation.  According to data collected in the National 
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Notifiable Disease Surveillance System (NNDSS) from 2004 to 2014 on HCV, Zibbell et 
al. (2018) found that six states (Kansas, Maine, Massachusetts, New Jersey, Ohio, and 
Wisconsin) of the 15 states studied showed an increase of over 1000% in the number of 
cases of acute HCV; with the greatest disparity and most significant increases in acute 
HCV in persons between 18 and 39 years of age. 
Disparities in disease burden among PWID and access to proper HCV therapy 
may lead to non-start treatment, even if diagnosed with HCV as well as inadequate 
awareness, detection, and gaps in the treatment of HCV, resulting in increased health 
costs, poor outcomes, and worsening health (Younossi et al., 2016)). This challenge is 
especially complicated in low socio-economic communities, Medicaid-covered groups, or 
poor populations with no insurance (Van Handel et al., 2016). 
 Globally, less than 5% of people infected with HCV are aware of their status and 
may go undiagnosed for years (Esterbrook et al., 2016). There is a disparity in the actual 
burden of HCV disease in marginalized groups like PWID because the actual population 
is difficult to quantify.  Although the CDC may extract data from the Census Bureau to 
make calculations about disease rates by demographic categories (e.g. age at diagnosis, 
race, ethnicity and sex), there is limited data on the actual number of PWID in the U.S.  
Therefore, roughly 1.9 million people infected with hepatitis may be left out of national 
statistics due to being members of marginalized groups such as the PWID, mentally ill, 
convicts, other substance abusers, and those who are homeless (Lansky et al., 2014).  One 
of the most substantial issues for PWID with HCV is treatment management and 
completion.  In some cases, it was noted that patients do not necessarily make decisions 
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to pursue treatment when it is available.  Those with education and knowledge of HCV 
among PWID (i.e., marginalized groups) are less likely to be infected; however, the 
number is small for those with knowledge of the disease (Harris & Rhodes, 2013). 
Effective treatments of patients with chronic HCV have been readily available for close 
to two decades (Bethea et al., 2017).  
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Chapter 3: Research Method 
Introduction 
The purpose of Chapter 3 is to describe and defend the various decisions made 
regarding the methodology and research design of the study.  Chapter 3 is subdivided as 
follows. In the first section, I identified possible research methodologies for the study and 
described my selection of a quantitative approach.  In the second section, I presented the 
research designs that are possible when using a quantitative methodology.  In the third 
section, I restated the research questions and hypotheses of the study.  In the fourth 
section, I identified the data source, NHANES, that I used in the study, and discussed 
NHANES’s sampling. NHANES is unique in that it is the only publicly available national 
survey that captures both environmental and clinical data, and it is unmatched by any 
secondary data source in content and size. As such, the NHANES survey, or program of 
studies, offers researchers a very useful tool for effectively assessing the health and 
nutritional status of adults and children in the United States (CDC, 2018).  In the fifth 
section, I extended a lean discussion of the data analysis pertaining to the research 
questions of the study.  In the sixth section, I offered an overview of reliability and 
validity and their applicability in this study. In the seventh section, I discussed the ethical 
factors relevant to this study. Lastly, in the eighth and final section, I have provided a 
brief summary of the research orientations of the study.  
Research Design and Rationale 
There is a consensus (Creswell, 2015; Jackson, 2015; Moustakas, 2014; Trochim, 
Donnelly, & Arora, 2015) among methodologists that the three main approaches to 
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research methodology are quantitative, qualitative, and mixed methods (i.e., a blending of 
quantitative and qualitative approaches).  There is also a consensus that none of the 
methodologies is intrinsically superior; each methodology has strengths and weaknesses.  
The choice of methodology is determined by factors such as the research topic, research 
questions, and focus of a study (Arora, 2015; Creswell, 2015; Jackson, 2015; Moustakas, 
2014; Trochim et al., 2015).  
Table 1 contains McNabb’s (2015) summary of the characteristics of, as well as 
differences between, the quantitative and qualitative research methodologies.  The main 
difference between quantitative and qualitative methods identified by McNabb is the 
subjective nature of qualitative methodology as compared to the objective nature of 
quantitative methodology. In relation to the concept of objectivity, McNabb noted that it 
is not necessarily the case that quantitatively oriented studies measure a single, genuine 
reality; rather, there is only a methodological assumption that such a reality exists and 
can be studied, which is a hallmark of post-positivism (Arora, 2015; Creswell, 2015; 
Jackson, 2015; Moustakas, 2014; Trochim et al., 2015).  According to McNabb and the 
other methodologists cited earlier, reality is assumed to consist solely of what is 
measurable.  Post positivists on the other hand, emphasize that in quantitative research, 
assumptions about measurement and reality are being made.  
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Table 1 
Differences Between Quantitative and Qualitative Research  
Philosophical Foundations Qualitative Research 
Designs 
Quantitative Research 
Designs 
Ontology (perceptions of 
reality) 
 
Researchers assume that 
multiple, subjectively 
derived realities can 
coexist. 
 
Researchers assume that a 
single, objective world 
exists. 
Epistemology (roles for the 
researcher) 
Researchers commonly 
assume that they must 
interact with their studied 
phenomena. 
 
Researchers assume that 
they are independent from 
the variables under study. 
 
Axiology (researchers’ 
values) 
Researchers overtly act in a 
value-laden and biased 
fashion. 
 
Researchers overtly act in a 
value-free and unbiased 
manner. 
 
Rhetoric (language styles) Researchers often use 
personalized, informal, and 
context-laden language. 
 
Researchers most often use 
impersonal, formal, and 
rule-based text. 
 
Procedures (as employed in 
research) 
Researchers tend to apply 
induction, multivariate, and 
multiprocess interactions, 
following context-laden 
methods. 
 
Researchers tend to apply 
deduction, limited cause-
and-effect relationships, 
with context-free methods. 
 
Note. Adapted from McNabb (2015, p. 225). 
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In the context of this study, quantitative methodology was required for 
quantifying the relationship between poverty and HCV status.  As noted in the literature 
cited in Chapters 1 and 2, there are many reasons that HCV is more prevalent among the 
poor; these reasons are subjective, inductive, and somewhat open ended, rendering them 
a better fit for qualitative than for quantitative methodology.  However, the focus of the 
study was on quantifying the diagnosis and treatment of HCV as a function of poverty, as 
such an analysis (a) could be carried out on the data available, and (b) addressed a gap in 
the literature by applying an odds ratio (OR) model. 
In keeping with McNabb’s (2015) recommendations, the findings of the study 
were based on assumptions of measurement objectivity, researcher independence, lack of 
bias, impersonal rhetoric, and deductive methods.  
There are 10 major research designs recognized in the literature on methodology 
(Arora, 2015; Creswell, 2015; Jackson, 2015; Moustakas, 2014; Trochim et al., 2015).  
Several of these designs were rapidly eliminated from consideration for the current study. 
For example, none of the designs applied in the qualitative methodological domain was 
applicable to the study. 
In quantitative methodology, the available research designs are experimental, 
quasi-experimental, correlational, and survey-based designs.  In experiments, researchers 
possess the ability to randomly assign subjects to different conditions in order to increase 
the internal validity of inferences about the effect of a treatment.  In the case of a public 
health study, an experimental approach is impossible, because researchers cannot 
administer diseases or randomly assign individuals to wellness versus disease groups.  In 
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a quasi-experiment, there are treatments or exposures, but the researcher does not control 
them.  In a correlational study, the variables under study exist naturally, and are not 
subject to researcher or real-world intervention.  The purpose of analysis is merely to 
measure the correlations.  A correlation design was adopted for this study.  
Target Population 
The population of the study was of American adults. For the purposes of the 
study, an adult is someone who was 18 years of age or older when interviewed by 
NHANES.  The population addressed by NHANES consisted of both adults and 
juveniles, but the adult population was targeted in this study.  
Sampling Procedures 
The sampling procedures of NHANES were pertinent to this study. No original 
sampling was carried out. NHANES used simple random sampling to (a) identify over 30 
million potential participants, and (b) approach (by telephone and mail) potential 
participants. Anyone who met the NHANES criterion of giving informed consent was 
sampled by NHANES.  
Power Analysis 
The statistical procedure used in this study is a logistic regression with four 
predictors, an alpha of .05, a desired power of .80, an odds ratio of 1.3, and two-tailed 
significance tests.  In order to rule out the potential of a false-positive result or Type I 
error, it was essential to determine the appropriate sample size, significance level, and 
effect size necessary to achieve an adequate level of power for my study.  Therefore, as 
depicted in Figure 1, the a priori analysis was conducted using the power analysis 
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software, G*Power 3.1.9.2. (Heinrich-Heine-Universität Düsseldorf; Faul et al., 2009).  
On the basis of parameters, that according to Cohen (2013), are standard for logistic 
regression (i.e., predictors, alpha, desired power, odds ratio and two tails), the 
recommended sample was 721. The sample collected from NHANES was over 2,000.  
 
Figure 1. A priori sample size analysis (NHANES, 2016). 
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Reliability and Validity of Data Source 
The National Health and Nutrition Examination Survey (NHANES) was the best 
publicly available quantitative data source for the study.  NHANES is a nationwide 
survey conducted by the National Center for Health Statistics (NCHS) and administered 
by the Centers for Disease Control and Prevention (CDC).).  NHANES samples 
Americans at random, and, has been able to sample thousands of people in each of its 
waves.  The NHANES survey includes demographics, nutrition, and health history 
questionnaires to collect data participants identified for the study. In addition, NHANES 
carries out diagnostic and treatment services through mobile clinics (CDC, 2018).   
NHANES is particularly useful in terms of analyzing HCV, because (a) the 
NHANES mobile clinics provide the capability of making diagnoses of HCV, and (b) the 
HCV questionnaires ask participants about their previous history with HCV, for example, 
if they have received treatment for this disease in the past.  The NHANES dataset is 
large, randomly drawn from the population, and based on a combination of medical 
history taking and researcher questioning; for these reasons, NHANES was the ideal 
dataset through which to answer the research questions of this study.  The 2015-2016 
NHANES dataset was used for the purposes of this study (NHANES 2016).  
The validity of a measure indicates whether that measure actually captures the 
phenomenon it is intended to capture.  The validity of HEQ030 (Ever told you have 
Hepatitis C?) depends partly on whether the diagnosis of HCV was made by a certified 
health authority. NHANES increased the validity of answers to HEQ030 by directing 
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NHANES interviews to reject any self-diagnoses or diagnoses not made by a certified 
medical professional.   
The reliability of a measure indicates whether the same answer would be given to 
the measure if solicited again. In the context of HEQ030, the issue of reliability arises in 
terms of whether (a) participants who were in fact diagnosed with HCV by a medical 
professional did not disclose this status in their NHANES interview, or (b) participants 
who were not in fact diagnosed with HCV by a medical professional reported that they 
were diagnosed with HCV in their NHANES interview.  One way of increasing the 
reliability of answers to this question is to allow participants to indicate that they do not 
know whether they were diagnosed with HCV, thus reducing some of the inaccurate 
responses to this question that might be offered by individuals who feel pressured to 
answer yes or no, despite not knowing or not remembering.   
For RQ2 (Is there a statistically significant relationship between being below the 
poverty line and being prescribed HCV medications?), the dependent variable was having 
been prescribed medicines to treat HCV.  In the 2017-2018 NHANES dataset, the 
prescription of HCV medications ws measured by the question HEQ040 (Ever prescribed 
meds treat Hepatitis C?), which is provided in Figure 2.   
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Figure 2. NHANES Question HEQ040. From 2015-2016 Data Documentation, 
Codebook, and Frequencies: Hepatitis, by National Health and Nutrition Examination 
Survey, 2016 (https://wwwn.cdc.gov/Nchs/Nhanes/2015-2016/HEQ_I.htm). In the public 
domain. 
 
The validity of HEQ040 depends partly on whether the prescription of HCV 
medication was made by a certified health authority. NHANES increased the validity of 
answers to HEQ040 by directing NHANES interviews to reject any self-medication 
options for this question. In the context of HEQ040, the issue of reliability arises in terms 
of whether (a) participants who were in fact prescribed HCV medicines did not disclose 
this status in their NHANES interview, or (b) participants who were not in fact prescribed 
HCV medicines reported that they were prescribed HCV medicines in their NHANES 
interview.  One way of increasing the reliability of answers to this question is to allow 
participants to indicate that they do not know whether they were prescribed HCV 
medicines, thus preventing some of the inaccurate responses to this question that might 
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be offered by individuals who feel pressured to answer yes or no, despite not knowing or 
not remembering.   
In both RQ1 and RQ2, the independent variable was poverty.  In the 2017-2018 
NHANES dataset, poverty was measured by Question INDFMPIR (Ratio of family 
income to poverty), which is provided in Figure 3.   
  
Figure 3. NHANES Question INDFMPIR. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
Respondents are not asked to furnish the ratio of family (which NHANES 
considers to be equivalent to “household”) income to poverty ratio directly. Rather, 
NHANES respondents are directed to provide data related to two other questions: (a) 
How many individuals are in the family (defined as legally related individuals living in 
the same house) of the respondent, and (b) What is the income of the family? The income 
of the family is measured through Question INDHHIN2 (Annual household income), on 
annual household income, which appears in Figure 4.  
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Figure 4. NHANES Question INDHHIN2. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
The reliability of INDHHIN2 is increased by allowing participants to refuse to 
provide an income or to indicate that they do not know their family income; thus, for 
INDHHIN2, data are only collected from those participants who claim to be aware of, 
and who wish to provide, their family income.  This figure is then divided by the number 
of people in the respondent’s household - Question DMDFMSIZ (Total number of people 
in the Family), which appears as Figure 5 – in order to yield family income adjusted for 
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the number of people in a family. Finally, NHANES takes this quotient and analyzes it 
with respect to the official poverty line in each separate U.S. state in order to calculate 
INDFMPIR, which appears as Figure 3. 
The validity of INDFMPIR is increased by NHANES adjustments for each state. 
NHANES notes that, in each state, the definition of poverty is slightly different, as 
factors such cost of living vary from state to state and can therefore influence the 
definition of poverty.  To calculate INDFMPIR, NHANES data analysts measure the 
ratio derived for each participant as a function of INDHHIN2 divided by DMDFMSIZ 
against each participant’s state’s definition of the poverty line.   
 
Figure 5. NHANES Question DMDFMSIZ. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
While NHANES’ adjustment of variables increases the likelihood that 
INDFMPIR is both a reliable and valid measure of poverty, this variable is vulnerable to 
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other deficiencies in reliability and validity that do not appear to be addressed in the 
NHANES dataset. One of the roots of the problem is that NHANES does not ask 
respondents (a) where they were diagnosed with HCV or prescribed HCV medications or 
(b) how poor they were at the time that they were diagnosed with HCV or prescribed 
HCV medications. Another problem is that the ratio INDFMPIR can mask actual 
individual poverty, as INDFMPIR is an aggregate variable.  Each of these problems 
reduce the reliability and validity of the data analyses for RQ2 and therefore require a full 
discussion and acknowledgement.  
The internal validity of RQ1 depends on the strength of inferences that can be 
drawn about the relationship between the independent variable of poverty and the 
dependent variable of having been diagnosed with HCV.  RQ1’s internal validity would 
be threatened if either the independent or dependent variables in this research question 
were not true measures of their targeted concepts. Considering the discussion of 
NHANES’ absence of a time component with respect to either HCV diagnosis or the 
poverty status of an individual, it could be the case that an individual who was not poor 
when diagnosed with HCV was poor by the time he or she was questioned about his or 
her HCV diagnosis by NHANES. It could also be the case that an individual who was 
poor when diagnosed with HCV was not poor by the time he or she was questioned about 
his or her HCV diagnosis by NHANES.  In either of these cases, the internal validity of 
RQ1 would be reduced, as the data analysis would no longer truly be measuring the link 
between poverty and likelihood of being diagnosed with HCV.  
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In precisely the same manner, the internal validity of RQ2 depends on the strength 
of inferences that can be drawn about the relationship between the independent variable 
of poverty and the dependent variable of having been prescribed HCV medications. 
RQ2’s internal validity would be threatened if either the independent or dependent 
variables in this research question were not true measures of their targeted concepts. In 
light of the discussion of NHANES’ absence of a time component with respect to either 
prescription of HCV medications or the poverty status of an individual, it could be the 
case that an individual who was not poor when prescribed HCV medicines, was poor by 
the time he or she was questioned about his or her HCV prescription history by 
NHANES.  It could also be the case that an individual who was poor when prescribed 
HCV medication was not poor by the time he or she was questioned about his or her 
HCV prescription history by NHANES.  In either of these cases, the internal validity of 
RQ2 would be reduced, as the data analysis would no longer truly be measuring the link 
between poverty and likelihood of having been prescribed HCV medicines.  
Variable Definitions and Operationalization 
For RQ1, the variable of income-to-poverty ratio was transformed. In NHANES, 
this variable reflects the ratio of income to poverty, with, for example, a ratio of 1 
indicating that income is right at the poverty line, 0.5 indicating that income is half of 
poverty levels, and 2 indicating that income is twice the poverty level.  This variable was 
recoded so as to be dichotomous, with 1 = individuals in poverty and 0 = individuals not 
in poverty. Having HCV was coded as 1, and not having HCV was coded as 0; any OR > 
1 for RQ1 will mean that an individual in poverty has a greater chance of having HCV 
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than an individual not in poverty.  Having been previously been prescribed HCV 
medicines was coded as 1, and not having been previously prescribed HCV medications 
was coded as 0; any OR > 1 for RQ2 means that an individual in poverty has a greater 
chance of having been prescribed HCV medications than an individual not in poverty.  
In RQ1 (Is there a statistically significant relationship between being below the 
poverty line and being diagnosed with HCV?), the dependent variable is having received 
a diagnosis of HCV. In the 2017-2018 NHANES dataset, the diagnosis of HCV is 
measured by the question HEQ030, which is provided in Figure 6 below.  
 
Figure 6. NHANES Question HEQ030. From 2015-2016 Data Documentation, 
Codebook, and Frequencies: Hepatitis, by National Health and Nutrition Examination 
Survey, 2016 (https://wwwn.cdc.gov/Nchs/Nhanes/2015-2016/HEQ_I.htm). In the public 
domain. 
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Data Analysis Plans 
Data analysis is discussed below for each of the research questions of the study.  
The first research question of the study was as follows: Is there a statistically significant 
relationship between being below the poverty line and being diagnosed with HCV? RQ1 
will be analyzed through the application of a multiple logistic regression model that 
reported an odds ratio for poverty as a predictor of HCV diagnosis.  The null hypothesis 
associated with RQ1 will be rejected if the p value of the OR for poverty is < .05. If the p 
value of the OR for poverty is < .05, and the OR is > 1, it will be concluded that being 
poor is associated with a significantly higher risk of having HCV.  After testing the null 
hypothesis for RQ1, the control variables of gender, race, and education level will be 
added in order to (a) determine whether there are subject changes in the p value and 
coefficient value of poverty with the addition of the covariates, and (b) estimate the 
independent effects of gender, race, and education level on the chances of having HCV.   
The second research question of the study was as follows:  Is there a statistically 
significant relationship between being below the poverty line and being prescribed HCV 
medications? For RQ2, the NHANES dataset already indicates which individuals had 
been prescribed HCV medications; therefore, there is already a dichotomous dependent 
variable available for logistic regression analysis of RQ2.   The null hypothesis associated 
with RQ2 will be rejected if the p value of the OR for poverty is < .05. If the p value of 
the OR for poverty is < .05, and the OR is < 1, it will be concluded that being poor is 
associated with a significantly higher risk of not having been prescribed HCV 
medications.  After testing the null hypothesis for RQ2, the control variables of gender, 
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race, and education level will be added in order to (a) determine whether there are 
significant changes in the p value and coefficient value of poverty with the addition of the 
covariates; and (b) estimate the independent effects of gender, race, and education level 
on the chances of having been previously prescribed HCV medications.   
The data analysis for the study also includes the control variables of gender, race, 
and education level.  Therefore, a discussion of these variables as they appear in 
NHANES has also been provided.  Figure 6 below contains the NHANES coding for 
gender, which is measure solely as male, female, or missing Figure 7 contains NHANES 
coding for gender.  There were 4,892 male (49.06%) and 5,079 (50.94%) female; a total 
of 9,971 participants in this study.   
 
Figure 7. NHANES Question RIAGENDR. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
Figure 8 below contains the NHANES coding for race. There were 3,066 Non-
Hispanic White (30.75%), 2,129 Non-Hispanic Black (21.35%), 1,921 Mexican 
Americans (19,26%).   
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Figure 8. NHANES Question RIDRETH3. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
Figure 9 below contains the NHANES coding for education level.  The number of 
participants with some college or an AA degree was 1,692.  There were 1,422 
participants who were college graduates or above; 1,236 participants that were high 
school graduates and GED or equivalent; 676 participants that were 9th through 11 grade 
or 12th grade without a diploma; and 688 participants that had less than a 9th grade 
education. The education level was missing for 4,252 participants or the participants 
chose not to report their education level.     
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Figure 9. NHANES Question DMDEDUC2. From Demographic Variables, by National 
Health and Nutrition Examination Survey, 2017 (https://wwwn.cdc.gov/Nchs/Nhanes 
/2015-2016/DEMO_I.htm#INDFMPIR). In the public domain. 
 
The reliability and validity of the NHANES coding for gender is limited by the 
absence of a category specifically for transgender or non-binary people.  The reliability 
and validity of the NHANES coding for race is limited by the absence of more specific 
categories for individuals in the ‘other’ category. Finally, the reliability and validity of 
the NHANES coding for education is limited by the absence of a category to distinguish 
between college graduates and holders of more advanced degrees, as well as by the 
consideration that an individual’s current educational status might be different from his or 
her educational status when first diagnosed with, or treated for, HCV. As was the case 
with the independent variable of poverty, the covariate of education might lack validity 
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with respect to the data analyses for both RQ1 and RQ2.  For example, if an individual 
was a child when diagnosed with HCV, then his or her educational status would not have 
been measured by NHANES. Essentially, many of the validity problems that arise in the 
study are due to the same factor, which is the passage of an indeterminate “period of 
time” between (a) HCV diagnosis or HCV prescriptions, and (b) NHANES’ data 
collection.  It is in this “period of time,” the poverty status of an individual, as well as his 
or her education level, could change substantially, threatening the validity of the data 
analyses.  One possible means of addressing this issue, at least at the covariate level, is to 
present results with the covariate of education dropped as well as with the covariate of 
education included.  However, because poverty is an independent variable in RQs 1 and 
2, it must be retained, and there does not appear to be a means of approaching data 
analysis that can reduce or eliminate the problems caused by the passage of time between 
HCV diagnosis or HCV prescriptions and NHANES’ data collection. 
Threats to Validity 
A threat to the internal validity of the data analysis for RQ1 as well as RQ2 is 
based on the possibility that the NHANES questions mask the individual respondent’s 
poverty.  In RQ1 and RQ2, the independent variable was poverty, and the dependent 
variable was having been diagnosed with HCV. For the variable of poverty in RQ1 and 
RQ2 to be valid, it must be a measure of an individual’s poverty – which, as noted above, 
could be threatened by the absence of a time component in the NHANES dataset, but 
which could also be threatened by the method that NHANES uses to measure individual 
poverty. In terms of RQ1 and RQ2, it is possible that the variable of household income 
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masks the income of the respondent; if, for example, the respondent earns nothing, 
whereas his or her current spouse earns $60,000, then the respondent himself or herself 
might meet the individual definition of poverty.  Even if a household- rather than 
individually based definition of poverty is considered appropriate, it is possible that a 
respondent who was poor when he or she was first diagnosed with HCV or prescribed 
HCV medications later entered a wealthier household.  
The preceding discussion suggests that both the reliability and validity of the data 
analyses for RQ 1 and RQ 2 depend on several assumptions, limitations, and other 
characteristics of the NHANES dataset and its data collection method.  In this respect, the 
issues are not those of psychometric reliability, such as those that might merit the 
calculation of Cronbach’s Alpha or test-retest reliability (Santos, 1999), because 
NHANES does not ask participants to respond to scales. In the context of HCV, 
NHANES either collects demographic data or yes / no responses to simple questions 
about HCV status, diagnosis, and treatment.  Therefore, the reliability and validity of 
NHANES need to be considered not in a psychometric sense, but in consideration of 
factors (whether rooted in data collection, data analysis, or both) that threaten the ability 
of NHANES to truly measure poverty, and, by extension, to be analyzable with respect to 
the relationship between poverty and HCV diagnosis or prescriptions. 
A concern related to reliability is that of response rate.  A response rate is the 
percentage of individuals in a sample who contribute data. In the NHANES methodology, 
individual respondents were sampled through a two-step process.  First, all eligible 
respondents were tabulated by number and age group; for example, in 2015-2016, there 
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were roughly 316.5 million Americans eligible for NHANES.  From the overall 
population, NHANES utilizes randomization to select a pool of individuals who would be 
approached by NHANES interviewers.  The response rate can be calculated as the ratio 
of all individuals who are approached by NHANES to the number of individuals who 
agree to participate in a NHANES interview.  
Lower response rates are associated with bias – that is, decreased reliability - 
emerging from the possibility that the answers that would have been given by individuals 
who choose not to respond to a survey instrument are significantly different from the 
answers that were given by the individuals who agreed to participate in a study.  The 
problem of non-response rate has been described by Massey (2012) as follows: 
A shift from a response rate of 95 percent to 90 percent, for example, introduces a 
small potential for non-response bias; the additional 5 percent of non-respondents need to 
be extremely different from the respondents to introduce substantial non-response bias. 
The potential is not so small when the response rate is 50 percent (i.e., one-half of 
eligible sample members are non-respondents). In this case, relatively small differences 
between respondents and non-respondents may yield significant biases. (Massey, 2012, p. 
89). 
As the current study is delimited to adult respondents to NHANES (that is, 
individuals who are at least 20 years of age in NHANES), it would be useful to present 
the non-response rates reported by NHANES (2018) for the 2015-2016 dataset.  
• For the sub-sample of NHANES respondents in the 20-29 age bracket, the 
non-response rate was 44.3%. 
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• For the sub-sample of NHANES respondents in the 30-39 age bracket, the 
non-response rate was 42.8%. 
• For the sub-sample of NHANES respondents in the 40-49 age bracket, the 
non-response rate was 43.4%. 
• For the sub-sample of NHANES respondents in the 50-59 age bracket, the 
non-response rate was 43.7%. 
• For the sub-sample of NHANES respondents in the 60-69 age bracket, the 
non-response rate was 44.5%. 
• For the sub-sample of NHANES respondents in the 70-79 age bracket, the 
non-response rate was 47.5%. 
• For the sub-sample of NHANES respondents 80 or over, the non-response rate 
was 57.6%. 
Therefore, the non-response rates for NHANES at each age bracket were quite 
high. These non-response rates will lower the reliability of the NHANES findings, which, 
in turn, will lower the reliability for the analyses of RQ1 and RQ2.  
Ethical Procedures 
The Walden University Institutional Review Board (IRB) approved the proposal 
on October 11, 2018 (IRB Proposal Approval #10-11-18-0187345).  The data for the 
study were drawn from a public source, the National Health and Nutrition Examination 
Survey (NHANES). De-identified data were used in this study.  No prior agreements 
were required to access the data. The human subjects surveyed by NHANES possess both 
privacy and anonymity from the researcher.  For this reason, there are no ethical issues 
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that require resolution in collecting data for the study.  The data are archival data, in that 
they pre-exist the study and can be collected prior to the beginning of the study, as they 
are publicly available.  The data are not secondary data, which would be data gathered 
for, or from, another study and thereby subject to some of the same ethical constraints as 
primary data collection (Creswell, 2015).  The main ethical constraint on the study is the 
obligation to collect and analyze the data as accurately as possible and to disseminate the 
findings of the study in a manner that can contribute to positive social change.  
Summary and Transition 
The purpose of Chapter 3 was to describe and defend the various decisions made 
regarding the methodology and research design of the study.  The first section consisted 
of an identification of possible research methodologies and the selection of the 
quantitative approach to research because of the nature of the study and the problem 
identified in Chapter 1.  
The second section consisted of an identification of quantitative research designs.  
The third section consisted of a restatement of the research questions and hypotheses of 
the study.  The fourth section consisted of an identification of the data sources to be 
utilized in the study.  The fifth section consisted of a discussion of data analysis 
pertaining to the research questions of the study.  The sixth section consisted of a 
discussion of reliability and validity.  The seventh section consisted of a discussion of 
ethical factors.  The findings presented in Chapter 4 are in alignment with the 
methodological orientations described and defended in Chapter 3.   
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Chapter 4: Results 
Introduction 
The focus of this research was applying statistical analysis to data from NHANES 
to (a) estimate the odds-based relationships between HCV (in terms of diagnosis and 
treatment) risk as a function of poverty and (b) provide synthesized explanations of how 
and why HCV appears to function differentially in terms of diagnosis and treatment 
among the poor. This purpose was achieved by answering the following research 
questions and testing their associated null hypotheses.  All statistical tests and figures 
were generated within Stata 15.0 software.  
RQ1:  Is there a statistically significant relationship between being below the poverty 
line and being diagnosed with HCV? 
H10:  The odds ratio (OR) of having HCV as a function of poverty = 1. 
H1A:  The OR of having HCV as a function of poverty ≠ 1. 
RQ2:  Is there a statistically significant relationship between being below the poverty 
line and being prescribed HCV medications?  
H20:  The OR of being prescribed HCV medications as a function of poverty = 1. 
H2A:  The OR of being prescribed HCV medications as a function of poverty ≠ 1. 
The purpose of Chapter 4 is to present the findings of the study.  The findings are 
presented in three sections.  First, the descriptive statistics of the findings are presented. 
Second, answers to the research questions of the study are provided.  Third, other 
inferential tests relevant to the research questions are presented. 
54 
 
Data Collection 
All data were collected from the 2015-2016 administration of NHANES.  Data 
were assembled from the survey in the period from November 1 to November 8, 2018.  
There were no discrepancies in data collection from the plan presented in Chapter 3.  
Results 
The results were based primarily on answering the following research questions 
and their associated null and alternate hypotheses.  
RQ1:  Is there a statistically significant relationship between being below the poverty 
line and being diagnosed with HCV? 
H10:  The odds ratio (OR) of having HCV as a function of poverty = 1. 
H1A:  The OR of having HCV as a function of poverty ≠ 1. 
RQ2:  Is there a statistically significant relationship between being below the poverty 
line and being prescribed HCV medications?  
H20:  The OR of being prescribed HCV medications as a function of poverty = 1. 
H2A:  The OR of being prescribed HCV medications as a function of poverty ≠ 1. 
Application of the Research Method 
Approval to conduct research was obtained on September 13, 2018.  The 
NHANES data source contained the best publicly available secondary data and did not 
require a data use agreement from the CDC.  The NHANES data from 2015 to 2016 were 
downloaded on November 2, 2018.  Variable labels and coding were assigned using 
variable definitions from the NHANES dictionary.  No patient identifiers were 
downloaded from NHANES.  All data are therefore both private and anonymous.  The 
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subsample size of 81 represented all 81 individuals who were diagnosed with HCV in the 
NHANES dataset. However, the actual sample size was 9,971, as the calculation of ORs 
required the inclusion of both diagnosed and non-diagnosed individuals.  
Descriptive Statistics 
The first descriptive statistic contained the proportion of respondents who were 
diagnosed with HCV. Of 8,332 respondents for whom HCV diagnostic data were 
available, 78 were diagnosed with HCV, whereas 8,254 were not diagnosed with HCV. 
The proportion of the sample that was diagnosed with HCV was therefore 0.94%, with a 
95% confidence interval ranging from 0.73% to 1.15% (see Figure 10). Of 9,971 
respondents for whom poverty data could be calculated, 2,343, or 23.50%, were below 
the poverty line. The 95% confidence interval for the proportion of NHANES 
respondents who were below the poverty line was from 22.67% to 24.33%.  
Additionally, of the respondents, the 78 diagnosed with HCV were asked whether 
or not they had been prescribed medications for HCV, and, of these individuals, 22, or 
0.26%, indicated that they had received prescriptions.  The 95% confidence interval for 
NHANES respondents who were prescribed medications for HCV was from 0.15% to 
0.37% (see Figure 11).  
56 
 
 
Figure 10. 95% confidence interval and point estimate, HCV diagnosis. 
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Figure 11. 95% confidence interval and point estimate, HCV medication prescription. 
 
RQ1 Findings 
The first research question of the study was as follows: Is there a statistically 
significant relationship between being below the poverty line and being diagnosed with 
HCV? In RQ1, the independent variable was being below the poverty line, the dependent 
variable was whether the respondent was diagnosed with HCV, and the control variables 
were gender, race, and education level.  The model for RQ1 was fit in two stages, with 
the first step being to calculate the OR of being diagnosed with HCV as a function of 
poverty, and the second step being to calculate the OR of being diagnosed with HCV as a 
function of poverty after taking the explanatory power of gender, race, and education 
level into account.  For maximum explanatory power, the OR models for RQ1 were 
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constructed additively, with one covariate added at a time to the base model in order to 
observe changes in the OR of the relationship between poverty and being diagnosed with 
HCV.      
The first model for RQ1 was the calculation of the likelihood of being diagnosed 
with HCV as a function of poverty.  In this model, being poor (coded as 1, with not being 
poor coded as 0) had an OR of 1.13, indicating that poor people were 1.13 times as likely 
as nonpoor people to be diagnosed with HCV, SE = 0.29, z = 0.46.  However, this OR 
was not statistically significant, p = .647, and its 95% confidence interval (0.68, 1.88) 
included 1, meaning an absence of effect.  Therefore, it appeared that being diagnosed 
with HCV was not a function of poverty. 
The second model for RQ1 was the calculation of the likelihood of being 
diagnosed with HCV as a function of poverty as well as gender.  In this model, being 
poor had an OR of 1.13, indicating that poor people were 1.13 times as likely as nonpoor 
people to be diagnosed with HCV, SE = 0.29, z = 0.46, but poverty was not a significant 
predictor, p = .647.  It should be noted that the OR of poverty did not change from the 
base model after gender was added as a covariate.  In terms of gender, it was found that 
men were 1.00 times as likely as women to be diagnosed with HCV (OR = 1.00, SE = 
0.23, z = 0.00, p = .999).  Therefore, gender on its own was not a significant predictor of 
being diagnosed with HCV, and the addition of gender to the model did not alter the OR 
of poverty as a predictor of being diagnosed with HCV. 
The third model for RQ1 was the calculation of the likelihood of being diagnosed 
with HCV as a function of poverty as well as gender and race.  In this model, being poor 
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had an OR of 1.05, indicating that poor people were 1.05 times as likely as nonpoor 
people to be diagnosed with HCV, SE = 0.28, z = 0.20, but poverty was not a significant 
predictor, p = .841.  It should be noted that the OR of poverty did not change significantly 
from the base model after gender and race were added as covariates.  In terms of gender, 
it was found that men were 1.01 times as likely as women to be diagnosed with HCV (OR 
= 1.01, SE = 0.23, z = 0.04, p = .969). Therefore, gender on its own was not a significant 
predictor of being diagnosed with HCV.  Next, the impact of race was calculated.  In 
comparison to the base race of Mexican, being White (OR = 0.83, SE = 0.28, z = -0.56, p 
= .577), being Black (OR = 1.19, SE = 0.40, z = 0.53, p = .596), being Asian (OR = 0.69, 
SE = 0.33, z = -0.75, p = .451), being Other (OR = 0.96, SE = 0.54, z = -0.08, p = .940), 
and being Other Hispanic (OR = 0.90, SE = 0.37, z = -0.25, p = .800) were not significant 
predictors of being diagnosed with HCV.  Because none of the comparison races was 
significant when compared to the base race of Mexican, it can be inferred that being 
Mexican was also not a significant predictor of being diagnosed with HCV. 
The fourth model for RQ1 (see Table 2) was the calculation of the likelihood of 
being diagnosed with HCV as a function of poverty as well as gender, race, and 
education.  In this model, being poor had an OR of 0.99, indicating that poor people were 
0.99 times as likely as nonpoor people to be diagnosed with HCV, SE = 0.38, z = -0.03, 
but poverty was not a significant predictor, p = .974. It should be noted that the OR of 
poverty did not change significantly from the base model after gender, race, and 
education were added as covariates.  In terms of gender, it was found that men were 1.00 
times as likely as women to be diagnosed with HCV (OR = 1.00, SE = 0.29, z = 0.00, p = 
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.996).  Therefore, gender on its own was not a significant predictor of being diagnosed 
with HCV. Next, the impact of race was calculated. In comparison to the base race of 
Mexican, being White (OR = 0.95, SE = 0.44, z = -0.10, p = .920), being Black (OR = 
1.07, SE = 0.51, z = 0.15, p = .883), being Asian (OR = 0.84, SE = 0.50, z = -0.28, p = 
.776), being Other (OR = 0.48, SE = 0.52,  z = -0.68, p = .494), and being Other Hispanic 
(OR = 0.88, SE = 0.48, z = -0.24, p = .808) were not significant predictors of being 
diagnosed with HCV.  Because none of the comparison races was significant when 
compared to the base race of Mexican, it can be inferred that being Mexican was also not 
a significant predictor of being diagnosed with HCV.   
Finally, education was added as a covariate, with the base group being individuals who 
had not had a ninth-grade education. In comparison to individuals who had not been to 
high school, individuals who had been to Grades 9-11 (OR = 0.99, SE = 0.71, z = -0.02, p 
= .985), individuals who were high school graduates (OR = 1.21, SE = 0.76, z = 0.30, p = 
.764), individuals who had had some college or who held an associate’s degree (OR = 
2.14, SE = 1.25, z = 1.30, p = .194), and individuals with a college degree or higher (OR 
= 1.37, SE = 0.87, z = 0.50, p = .621) were not significantly more likely to have been 
diagnosed with HCV.  Because none of the comparison education groups was significant 
when compared to the base education group of no high school, it can be inferred that not 
having attended high school was also not a significant predictor of being diagnosed with 
HCV. HCV. 
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Table 2 
OR Results, RQ1 (Dependent Variable: Diagnosed With HCV) 
Independent variable OR SE z p 
95% CI, 
lower 
bound 
95% CI, 
upper bound 
Being poor 0.988 0.381 -0.030 0.974 0.464 2.102 
Being male 1.001 0.290 < .001 0.996 0.568 1.766 
Being Hispanic 0.875 0.480 -0.240 0.808 0.300 2.564 
Being White 0.955 0.437 -0.100 0.920 0.390 2.340 
Being Black 1.073 0.512 0.150 0.883 0.421 2.734 
Being Asian 0.844 0.504 -0.280 0.776 0.216 2.721 
Being other race 0.480 0.515 -0.680 0.494 0.058 3.940 
9-11 grade  0.987 0.710 -0.020 0.985 0.241 4.032 
HS graduate 1/208 0.757 0.300 0.764 0.353 4.130 
Some college 2.135 1.248 1.300 0.194 0.679 6.715 
College or above 1.369 0.868 0.500 0.621 0.395 4.740 
Constant  0.007 0.004 -8.380 0.001 0.002 0.023 
Note. To 3 significant figures.  
 
The fourth OR model for RQ1 passed the Pearson chi-square goodness-of-fit 
assumption, chi-square (106) = 100.24, p = .6395.  
RQ2 Findings 
The second research question of the study was as follows: Is there a statistically 
significant relationship between being below the poverty line and being prescribed HCV 
medications?  In RQ2, the independent variable was being below the poverty line, the 
dependent variable was whether the respondent was prescribed HCV medications, and 
the control variables were gender, race, and education level. The model for RQ2 was fit 
in two stages, with the first step being to calculate the OR of being prescribed HCV 
medications as a function of poverty, and the second step being to calculate the OR of 
being prescribed HCV medications as a function of poverty after taking the explanatory 
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power of gender, race, and education level into account.  For maximum explanatory 
power, the OR models for RQ2 were constructed additively, with one covariate added at a 
time to the base model in order to observe changes in the OR of the relationship between 
poverty and being prescribed HCV medication.   
The first model for RQ2 was the calculation of the likelihood of being prescribed 
HCV medications as a function of poverty.  In this model, being poor (coded as 1, with 
not being poor coded as 0) had an OR of 1.73, indicating that poor people were 1.73 
times as likely as nonpoor people to be prescribed HCV medication, SE = 1.00, z = 0.94. 
However, this OR was not statistically significant, p = .346, and its 95% confidence 
interval (0.55, 5.38) included 1, meaning an absence of effect.  Therefore, it appeared that 
being prescribed HCV medications was not a function of poverty. 
The second model for RQ2 was the calculation of the likelihood of being 
prescribed HCV medications as a function of poverty as well as gender.  In this model, 
being poor had an OR of 1.89, indicating that poor people were 1.89 times as likely as 
nonpoor people to be prescribed HCV medication, SE = 1.12, z = 1.07, but poverty was 
not a significant predictor, p = .285.  It should be noted that the OR of poverty did not 
change from the base model after gender was added as a covariate.  In terms of gender, 
men were 0.61 times as likely as women to be prescribed HCV medication (OR = 0.61, 
SE = 0.33, z = -0.91, p = .361).  Therefore, gender on its own was not a significant 
predictor of being prescribed HCV medications, and the addition of gender to the model 
did not alter the OR of poverty as a predictor of being prescribed HCV medications. 
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The third model for RQ2 was the calculation of the likelihood of being prescribed 
HCV medications as a function of poverty as well as gender and race.  In this model, 
being poor had an OR of 1.64, indicating that poor people were 1.64 times as likely as 
non-poor people to be prescribed HCV medication, SE = 1.05, z = 0.77, but poverty was 
not a significant predictor, p = .441.  It should be noted that the OR of poverty did not 
change significantly from the base model after gender and race were added as covariates.  
In terms of gender, men were 0.75 times as likely as women to be prescribed HCV 
medication (OR = 0.74, SE = 0.42, z = -0.51, p = .609).  Therefore, gender on its own was 
not a significant predictor of being prescribed HCV medications.  Next, the impact of 
race was calculated. In comparison to the base race of Mexican, being White (OR = 0.36, 
SE = 0.31, z = -1.19, p = .234), being Black (OR = 1.03, SE = 0.76, z = 0.04, p = .969), 
being Other (OR = 0.51, SE = 0.68, z = -0.51, p = .612), and being Other Hispanic (OR = 
2.14, SE = 1.91, z = 0.85, p = .397) were not significant predictors of being prescribed 
HCV medications.  Because no Asians were prescribed HCV medications, being Asian 
could not be included in the logistic regression.  Finally, because none of the included 
comparison races was significant when compared to the base race of Mexican, it can be 
inferred that being Mexican was also not a significant predictor of being prescribed HCV 
medications.  
The fourth model for RQ2 (see Table 3 below) was the calculation of the 
likelihood of being prescribed HCV medications as a function of poverty as well as 
gender, race, and education.  In this model, being poor had an OR of 0.32, indicating that 
poor people were 0.32 times as likely as non-poor people to be prescribed HCV 
64 
 
medication, SE = 0.55, z = -0.66, but poverty was not a significant predictor, p = .507.  It 
should be noted that the OR of poverty did not change significantly from the base model 
after gender, race, and education were added as covariates.  In terms of gender, men were 
1.60 times as likely as women to be prescribed HCV medication (OR = 1.60, SE = 1.52, z 
= 0.50, p = .617).  Therefore, gender on its own was not a significant predictor of being 
prescribed HCV medications.  Next, the impact of race was calculated.  In comparison to 
the base race of Mexican, being White (OR = 0.19, SE = 0.30, z = -1.04, p = .299), being 
Black (OR = 0.42, SE = 0.65, z = -0.56, p = .577), and being Other Hispanic (OR = 2.40, 
SE = 4.17, z = 0.50, p = .507) were not significant predictors of being prescribed HCV 
medications.  Members of Asian and Other races were excluded because of not being 
prescribed HCV medications.  Because none of the included comparison races was 
significant when compared to the base race of Mexican, it can be inferred that being 
Mexican was also not a significant predictor of being prescribed HCV medications.  
Finally, education was added as a covariate, with the base group being individuals who 
had not had a 9th-grade education.  In comparison to individuals who had not been to 
high school, individuals who had been to grades 9-11 (OR = 0.32, SE = 0.60, z = -0.61, p 
= .540), individuals who were high school graduates (OR = 0.51, SE = 0.64, z = -0.54, p = 
.588), and individuals who had had some college or who held an Associate’s degree (OR 
= 0.16, SE = 0.21, z = -1.40, p = .162) were not significantly more likely to have been 
diagnosed with HCV.  The education class of college above was excluded because none 
of its members were prescribed HCV medications. Because none of the included 
comparison education groups was significant when compared to the base education group 
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of no high school, it can be inferred that not having attended high school was also not a 
significant predictor of being prescribed HCV medications.    
Table 3 
OR Results, RQ1 (Dependent Variable: Prescribed HCV Medicines) 
Independent 
variable OR SE z p 
95% CI, 
lower 
bound 
95% CI, 
upper 
bound 
Being poor 0.322 0.550 -0.660 0.507 0.011 9.188 
Being male 1.605 1.520 0.500 0.617 0.250 10.274 
Being 
Hispanic 
2.396 4.163 0.500 0.615 0.079 72.327 
Being 
White 
0.189 0.303 -1.040 0.299 0.008 4.392 
Being 
Black 
0.416 0.650 -0.560 0.575 0.019 8.908 
Being 
Asian 
-- -- -- -- -- -- 
Being other 
race 
-- -- -- -- -- -- 
9-11 grade  0.326 0.596 -0.610 0.540 0.009 11.722 
HS 
graduate 
0.506 0.636 -0.540 0.588 0.042 5.950 
Some 
college 
0.160 0.210 -1.400 0.162 0.012 2.092 
College or 
above 
-- -- -- -- -- -- 
Constant  1.661 2.645 0.320 0.750 0.073 37.662 
Note. To 3 significant figures.  
 
The fourth OR model for RQ2 passed the Pearson Chi-square goodness-of-fit 
assumption, Chi-square (106) = 26.13, p = .0567. 
Additional Inferential Statistics 
Because of the wealth of data in the NHANES dataset, and because no 
statistically significant findings emerged from the analysis of the research questions, the 
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opportunity was taken to examine the influence of two other possible confounding 
variables, including having any health insurance and having Medicaid. 
Health Insurance Effects 
Health insurance effects were tested separately for RQ1 and RQ2. For RQ1, 
health insurance was added to the final model, that is, the model in which poverty, 
gender, race, and education were present as predictors of having been diagnosed with 
HCV. For RQ2, health insurance was also added to the final model, in which poverty, 
gender, race, and education were present as predictors of having been prescribed HCV 
medication.  
The health insurance model for RQ1 (see Table 4) was the calculation of the 
likelihood of being diagnosed with HCV as a function of poverty, health insurance, 
gender, race, and education.  In this model, being poor had an OR of 0.89, indicating that 
poor people were 0.89 times as likely as non-poor people to be diagnosed with HCV, SE 
= 0.34, z = -0.31, but poverty was not a significant predictor, p = .755.  It should be noted 
that the OR of poverty did not change significantly from the base model after health 
insurance, gender, race, and education were added as covariates.  In terms of health 
insurance, individuals with health insurance were 0.49 times as likely as individuals 
without health insurance to be told that they had HCV, and this OR was significant (OR = 
0.49, SE = 0.17, z = -2.08, p = .038).  In terms of gender, men were 0.97 times as likely as 
women to be diagnosed with HCV (OR = 0.97, SE = 0.28, z = -0.11, p = .914).  
Therefore, gender on its own was not a significant predictor of being diagnosed with 
HCV when health insurance was added as a covariate to the expanded model for RQ1.    
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Table 4 
OR Results, Health Insurance Model (Dependent Variable: Diagnosed With HCV) 
Independent 
variable OR SE z p 
95% CI, 
lower 
bound 
95% CI, 
upper 
bound 
Being poor 0.886 0.345 -0.310 .755 0.413 1.900 
Being male 0.970 0.281 -0.110 .914 0.549 1.710 
Being 
Hispanic 
0.933 0.513 -0.130 .900 0.318 2.734 
Being 
White 
1.100 0.512 0.200 .841 0.440 2.734 
Being 
Black 
1.195 0.577 0.370 .712 0.464 3.076 
Being 
Asian 
0.944 0.570 -0.090 .924 0.289 3.077 
Being other 
race 
0.524 0.564 -0.600 .549 0.063 4.323 
9-11 grade  0.980 0.704 -0.030 .977 0.250 4.008 
HS 
graduate 
1.233 0.774 0.330 .738 0.360 4.222 
Some 
college 
2.284 1.340 1.410 .159 0.723 7.211 
College or 
above 
1.558 0.997 0.690 .488 0.445 5.463 
Insured 0.486 0.169 -2.080 .038 0.245 0.960 
Constant  0.012 0.007 -7.270 <.001 0.003 0.039 
Note. To 3 significant figures.  
Next, the impact of race was calculated. In comparison to the base race of 
Mexican, being White (OR = 1.10, SE = 0.51, z = -0.13, p = .900), being Black (OR = 
1.19, SE = 0.58, z = 0.37, p = .712), being Asian (OR = 0.94, SE = 0.57, z = -0.09, p = 
.924), being Other (OR = 0.52, SE = 0.56,  z = -0.60, p = .549), and being Other Hispanic 
(OR = 0.93, SE = 0.51, z = -0.13, p = .900) were not significant predictors of being 
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diagnosed with HCV. Because none of the comparison races was significant when 
compared to the base race of Mexican, it can be inferred that being Mexican was also not 
a significant predictor of being diagnosed with HCV when health insurance was added as 
a covariate to the expanded model for RQ1.  Finally, education was added as a covariate, 
with the base group being individuals who had not had a 9th-grade education.  In 
comparison to individuals who had not been to high school, individuals who had been to 
Grades 9-11 (OR = 0.98, SE = 0.70, z = -0.03, p = .977), individuals who were high 
school graduates (OR = 1.23, SE = 0.77, z = 0.33, p = .738), individuals who had had 
some college or who held an Associate’s degree (OR = 2.28, SE = 1.34, z = 1.41, p = 
.159), and individuals with a college degree or higher (OR = 1.56, SE = 1.00, z = 0.69, p 
= .488) were not significantly more likely to have been diagnosed with HCV.  Because 
none of the comparison education groups was significant when compared to the base 
education group of no high school, it can be inferred that not having attended high school 
was also not a significant predictor of being diagnosed with HCV. 
In terms of RQ1, the addition of having health insurance did not alter the non-
significance of any of the variables in the initial model (that is, poverty, gender, race, and 
education).  However, having health insurance was, on its own, a significant predictor of 
being diagnosed with HCV. Specifically, individuals without health insurance were 
almost twice as likely to be diagnosed with HCV as individuals without health insurance.  
This cross-tabulation appears as Table 5 below. 
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Table 5 
Cross-Tabulation of Health Insurance Status and HCV Diagnosis 
Ever told you have 
HCV? 
Health insurance status Total 
 Not insured Insured  
No 1,084 (98%)) 7,154 (99%) 8,238 (99%) 
Yes 17 (2%) 61 (1%) 78 (1%) 
Total 1,101 (100%) 7,215 (100%) 8,316 (100%) 
 
Pearson’s χ2 for the data in Table 2 is 5.02, p = .025.  A higher-than-expected 
proportion of individuals diagnosed with HCV were not insured. As will be discussed 
further in Chapter 5, this finding suggests the possibility that uninsured individuals might 
be tested for HCV through other means, such as mobile medical clinics, free clinics, or 
research studies.  
The health insurance model for RQ2 was the calculation of the likelihood of being 
prescribed medications for HCV as a function of poverty, health insurance, gender, race, 
and education. In this model, being poor had an OR of 0.01, indicating that poor people 
were 0.01 times as likely as non-poor people to be diagnosed with HCV, SE = 0.03, z = -
1.69, but poverty was not a significant predictor, p = .091.  It should be noted that the OR 
of poverty did not change significantly from the base model after health insurance, 
gender, race, and education were added as covariates.  In terms of health insurance, 
individuals with health insurance were 0.03 times as likely as individuals without health 
insurance to be prescribed HCV medications, and this OR was significant (OR = 0.05, SE 
= -2.11, z = -2.08, p = .035).  In terms of gender, men were 1.57 times as likely as women 
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to be diagnosed with HCV (OR = 1.57, SE = 1.81, z = 0.39, p = .698).  Therefore, gender 
on its own was not a significant predictor of being prescribed medications for HCV when 
health insurance was added as a covariate to the expanded model for RQ2.  Next, the 
impact of race was calculated. In comparison to the base race of Mexican, being White 
(OR = 1.15, SE = 2.22, z = 0.07, p = .372), being Black (OR = 2.18, SE = 4.18, z = 0.41, p 
= 685), and being Other Hispanic (OR = 7.00, SE = 15.27, z = 0.89, p = .900) were not 
significant predictors of being prescribed medications for HCV (note that the classes of 
Asian and Other were empty and therefore not included in this logistic regression).  
Because none of the included comparison races was significant when compared to the 
base race of Mexican, it can be inferred that being Mexican was also not a significant 
predictor of being prescribed medications for HCV when health insurance was added as a 
covariate to the expanded model for RQ2.  Finally, education was added as a covariate, 
with the base group being individuals who had not had a 9th grade education. In 
comparison to individuals who had not been to high school, individuals who had been to 
grades 9-11 (OR = 0.20, SE = 0.42, z = -0.76, p = .449), individuals who were high 
school graduates (OR = 0.27, SE = 0.37, z = -0.96, p = .339), and individuals who had 
had some college or who held an Associate’s degree (OR = 2.28, SE = 1.34, z = 1.41, p = 
.159), and individuals with a college degree or higher (OR = 0.05, SE = 0.09, z = -1.69, p 
= .091) were not significantly more likely to have been diagnosed with HCV (note that 
the class of individuals with college degrees or higher was empty and therefore excluded 
from this analysis).  Because none of the included comparison education groups was 
significant when compared to the base education group of no high school, it can be 
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inferred that not having attended high school was also not a significant predictor of being 
prescribed medications for HCV. 
In terms of RQ2, the addition of having health insurance did not alter the non-
significance of any of the variables in the initial model (that is, poverty, gender, race, and 
education).  One point of interest arising from the addition of health insurance to the 
model for RQ2 is that, when health insurance is isolated from the other covariates, it is no 
longer a statistically significant predictor of being prescribed HCV medications.  For 
example, Chi-square analysis indicates that the distribution of individuals in the HCV 
medication groups by health insurance status does not violate the null assumption, as 
Pearson’s χ2 for the data in Table 6 is 3.15, p = .076.  
Table 6 
Cross-Tabulation of Health Insurance Status and Being Prescribed HCV Medications 
Ever prescribed 
HCV medication? 
Health insurance status Total 
 Not insured Insured  
No 8 (50%) 39 (74%) 47 
Yes 8 (50%) 14 (26%) 22 
Total 16 53 69 
 
In addition, when health insurance is the sole predictor in a logistic regression 
model with having been prescribed HCV medications as the dependent variable, health 
insurance is not a significant predictor (OR = 0.36, SE = 0.21, z = -1.74, p = .082).  Thus, 
the significance of health insurance as a predictor of being prescribed HCV medications 
only exists in the combined model, indicating that the other demographic variables 
interact somehow to make health insurance significant in the expanded model.   
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Medicaid Effects 
Medicaid effects were tested separately for RQ1 and RQ2.  For RQ1, Medicaid 
was added to the final model, that is, the model in which poverty, gender, race, and 
education were present as predictors of having been diagnosed with HCV.  For RQ2, 
Medicaid was also added to the final model, in which poverty, gender, race, and 
education were present as predictors of having been prescribed HCV medication.  
The Medicaid model for RQ1 was the calculation of the likelihood of being 
diagnosed with HCV as a function of poverty, Medicaid, gender, race, and education.  In 
this model, being poor had an OR of 1.05, indicating that poor people were 1.05 times as 
likely as non-poor people to be diagnosed with HCV, SE = 0.42, z = 0.13, but poverty 
was not a significant predictor, p = .900. It should be noted that the OR of poverty did not 
change significantly from the base model after Medicaid, gender, race, and education 
were added as covariates.  In terms of Medicaid, individuals with Medicaid were 0.75 
times as likely as individuals without Medicaid to be told that they had HCV, but this OR 
was not significant (OR = 0.75, SE = 0.38, z = -0.57, p = .568). In terms of gender, men 
were 0.99 times as likely as women to be diagnosed with HCV (OR = 0.99, SE = 0.29, z 
= -0.03, p = .973).  Therefore, gender on its own was not a significant predictor of being 
diagnosed with HCV when Medicaid was added as a covariate to the expanded model for 
RQ1.   Next, the impact of race was calculated. In comparison to the base race of 
Mexican, being White (OR = 0.96, SE = 0.44, z = -0.09, p = .931), being Black (OR = 
1.10, SE = 0.53, z = 0.20, p = .840), being Asian (OR = 0.85, SE = 0.51, z = -0.26, p = 
.792), being Other (OR = 0.49, SE = 0.52, z = -0.67, p = .505), and being Other Hispanic 
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(OR = 0.88, SE = 0.48, z = -0.23, p = .820) were not significant predictors of being 
diagnosed with HCV.  Because none of the comparison races was significant when 
compared to the base race of Mexican, it can be inferred that being Mexican was also not 
a significant predictor of being diagnosed with HCV when Medicaid was added as a 
covariate to the expanded model for RQ1.  Finally, education was added as a covariate, 
with the base group being individuals who had not had a 9th-grade education.  In 
comparison to individuals who had not been to high school, individuals who had been to 
Grades 9-11 (OR = 0.98, SE = 0.71, z = -0.02, p = .983), individuals who were high 
school graduates (OR = 1.19, SE = 0.75, z = 0.28, p = .777), individuals who had had 
some college or who held an Associate’s degree (OR = 2.10, SE = 1.23, z = 1.27, p = 
.206), and individuals with a college degree or higher (OR = 1.33, SE = 0.84, z = 0.44, p 
= .657) were not significantly more likely to have been diagnosed with HCV.  Because 
none of the comparison education groups was significant when compared to the base 
education group of no high school, it can be inferred that not having attended high school 
was also not a significant predictor of being diagnosed with HCV. In terms of RQ1, the 
addition of having Medicaid did not alter the non-significance of any of the variables in 
the initial model (that is, poverty, gender, race, and education), and Medicaid also failed 
to be a significant predictor of being diagnosed with HCV when included with the 
covariates of poverty, gender, race, and education.  For RQ2, because no individuals who 
had Medicaid were prescribed HCV medications, the logistic regression model could not 
be carried out.  
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Prescription as a Function of Diagnosis 
Another analytical procedure carried out on the data was to model the likelihood 
of being prescribed HCV medications after being diagnosed with HCV.  Seventy-eight 
individuals in the sample were diagnosed with HCV, and 22 of these individuals were 
prescribed HCV medication. Thus, the point estimate of the likelihood of being 
prescribed HCV medication was 22 / 78, or roughly 28.20%, with a confidence interval 
of 18.21% to 38.19%.  Thus, there is substantial variability in the likelihood of a person 
with HCV being prescribed HCV medications.   
Summary 
The purpose of Chapter 4 was to present the findings of the study.  The findings 
were presented in three sections.  First, the descriptive statistics were presented. Second, 
answers to the research questions of the study were provided.  Third, other inferential 
tests relevant to the research questions were presented. 
To summarize the first research question, it was found that there was not a 
statistically significant relationship between being below the poverty line and being 
diagnosed with HCV when gender, race, and education were also included as covariates, 
OR = 0.99 (SE = 0.38, z = -0.03, p = .974).  To summarize the second research question, 
it was found that there was not a statistically significant relationship between being below 
the poverty line and being prescribed HCV medications when gender, race, and education 
were also included as covariates, OR = 0.32 (SE = 0.55, z = -0.66, p = .507).  It was 
found, unexpectedly, that having health insurance was associated with a significantly 
lower chance of being diagnosed with HCV, OR = 0.49 (SE = 0.17, z = -2.08, p = .038); 
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the public health implications of this finding, and the other findings of the study, have 
been discussed in Chapter 5.  
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Chapter 5: Conclusion 
Introduction 
The focus of this research was applying statistical analysis to data from NHANES 
to (a) estimate the odds-based relationships between HCV risk (in terms of diagnosis and 
treatment) as a function of poverty, and (b) provide synthesized explanations of how and 
why HCV appears to function differentially in terms of diagnosis and treatment among 
the poor.  The purposes of Chapter 5 are to discuss the findings of the study, make 
recommendations for practice and future scholarship, and acknowledge the limitations of 
the study.  The discussion relates the findings of the study to the theoretical framework 
discussed in Chapter 2. One of the main recommendations for future practice is to learn 
both how and why (i.e., through a mixed-methods approach) HCV diagnosis appears to 
be significantly higher for individuals who do not have health insurance. 
Interpretation of the Findings 
The purpose of the study was to apply statistical analysis to data from NHANES 
in order to (a) estimate the odds-based relationships between HCV (in terms of diagnosis 
and treatment) risk as a function of poverty, and (b) provide synthesized explanations of 
how and why HCV appears to function differentially in terms of diagnosis and treatment 
among the poor. This purpose was approached through two research questions:  
RQ1:  Is there a statistically significant relationship between being below the poverty 
line and being diagnosed with HCV?  
RQ2:  Is there a statistically significant relationship between being below the poverty 
line and being prescribed HCV medications?   
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As noted in Chapter 4, the answer to the first research question was that there was 
not a statistically significant relationship between being below the poverty line and being 
diagnosed with HCV when gender, race, and education were also included as covariates, 
OR = 0.99 (SE = 0.38, z = -0.03, p = .974), and the answer to the second research 
question was that there was not a statistically significant relationship between being 
below the poverty line and being prescribed HCV medications when gender, race, and 
education were also included as covariates, OR = 0.32 (SE = 0.55, z = -0.66, p = .507).   
The findings of the study can be discussed with respect to the two theoretical 
frameworks of the study.  The first framework, that of the HBM, was taken to suggest 
that the poor might incur HCV at disproportionate rates because of their differential 
beliefs about disease transmission, management, and cure.  The second framework, that 
of the PHSA, was taken to suggest that the public health of the poor might not rise to the 
full attention of the policy establishment, thus providing theoretical underpinnings for the 
research questions of the study; in the discussion of positive social change implications, 
the role of the current study in contributing to the establishment of poverty as an agenda 
item in public health has been specially noted. 
In terms of the PHSA, it is important to note that, because having health insurance 
was associated with a significantly lower chance of being diagnosed with HCV, OR = 
0.49 (SE = 0.17, z = -2.08, p = .038), it seems that public health authorities might have 
adequate methods in place for screening the poor for HCV. As noted in Chapter 3, the 
statistical analysis in Chapter 4 relied upon a specific operational definition of poverty 
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obtained from the NHANES dataset.  This measure of poverty failed to be a significant 
predictor of either being diagnosed with HCV or being prescribed HCV medications.   
It could be the case that the variable of poverty, as operationally defined in the 
study, was not as valid a measure of true poverty as not having health insurance.  If it is 
assumed that not having health insurance is a better measurement of poverty than the 
income-to-family-member ratio described in Chapter 3, then it is important to note that 
individuals without health insurance were (a) more likely to be diagnosed with HCV, and 
(b) not less likely to be prescribed HCV medications.  Especially in respect to the PHSA, 
the findings related to health insurance indicated that public health authorities might in 
fact be prioritizing the poor by providing diagnostic services through mobile clinics, 
research studies, free clinics, or other means.  Similarly, the finding that individuals’ 
HCV medication prescriptions do not vary depending on either poverty or health 
insurance status suggested that the poor are not systematically deprioritized in terms of 
their access to prescription medications for HCV, but, because of the cross-sectional 
design of the study, this interpretation was not necessarily supported by the statistical 
data analysis procedures. 
The interpretation of the PHSA provided in Chapter 1 and 2 of the study indicates 
that in a public health environment, in which the poor are not prioritized or even treated 
equitably, the poor will be (a) less likely to be diagnosed with HCV, and (b) less likely to 
be prescribed medication for HCV.  Neither of these predictions, made by the PHSA, as 
found in Falade-Nwulia et al.’s (2016) study, was borne out by the findings presented in 
Chapter 4. The scope of the current study does not allow speculation on how and why the 
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poor might be equitably treated by public health authorities, because the cross-sectional 
approach of the study posed important limitations in this context; however, in the 
recommendations for future study, there are discussions of potentially appropriate mixed-
method approaches to learning more about public health attention to HCV among the 
poor. 
One possible interpretation of the HBM is that poor people are less likely to know 
their health status and less likely to seek treatment. Empirically, the HBM suggested that 
poor people would be less likely to know their HCV status and less likely to have been 
prescribed medicine for HCV (Solomon et al., 2015).  Neither of these predictions were 
supported by the empirical analysis presented in Chapter 4.  The PHSA suggests that 
poverty’s failure to predict differences in HCV diagnostic or prescriptive status is a 
possible result of public health authorities’ proactivity and diligence in serving the poor, 
whereas the HBM framework suggests that poor people might be no different than the 
nonpoor in terms of seeking out appropriate care and medication.  
In this manner, the PHSA and HBM provide complementary explanations for the 
absence of significant findings in the current study.  The HBM suggests that poor 
people’s knowledge of their HCV status and history of prescriptions are functions of poor 
people’s own beliefs and behaviors about the importance of learning about and managing 
their health.  The PHSA suggests that the reason for the equality between the poor and 
nonpoor in terms of HCV diagnoses and prescriptions is a function of the diligence of 
public health authorities.  The recommendations for further study, offered subsequently 
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in the chapter, include a discussion of how mixed-methods research designs can better 
isolate and measure the relative importance of the HBM and PHSA. 
Limitations of the Study 
The study had numerous limitations. Each limitation has been discussed 
separately. Several of the recommendations have been taken as bases for suggestions for 
future scholarly research as provided in the next subsection of the chapter.  
First, one of the main limitations, applicable to both RQ1 and RQ2, was that 
relatively few individuals who participated in NHANES were either diagnosed with 
HCV, or given prescription medications for HCV.  One of the reasons that a small sample 
size is a limitation for OR calculations, is that the smaller the sample, the larger the 95% 
confidence interval of an OR (Jackson, 2015).  In practical terms, this limitation means 
that when sample sizes are small, OR calculations will only identify very large 
differences.  If there exist small but still statistically significant differences between 
comparison groups, if at least one of these groups is small in number of members, then 
the OR calculations will fail to identify significant differences (Jackson, 2015). 
A second, more general limitation of the study, is that the concept of poverty 
might have had a narrow specification space.  One of the intrinsic limitations of the 
study, is the possibility that it had low specification space, a concept that has been of 
previous concern to statistical methodologists (Leamer, 1983; Roodman, 2007).  
Roodman (2007), citing the pioneering work of Leamer (1983) in the domain of 
specification space, suggested that many statistical analyses might be arbitrary in that 
they fail to capture sufficiently dimensions of a research problem or concept. 
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Roodman (2007) and Leamer (1983) studies differ not only in their conclusions 
but in their specifications as well. Although probably none of the choices are made on a 
whim; these differences appear to be examples of what Leamer (1983) called “whimsy.” 
From Leamer’s point of view, both studies  represent a small sampling of specification 
space. Few include much robustness testing.  Without further analysis, it is hard to know 
whether the results reveal solid underlying regularities in the data or are fragile artefacts 
of certain specification choices (Roodman, 2007, p. 262). 
Chapter 3 contained a discussion of the means whereby a poverty variable was 
generated for statistical analysis.  It is possible that this approach did not constitute a 
valid measurement of poverty. One indication that the chosen means of operationalizing 
poverty might have failed in terms of specification space is that the variable of having 
health insurance, which can be considered an appropriate proxy variable for poverty, was 
statistically significant when added to the analyses for RQ1 and RQ2.  The different 
results generated by these two possible measures of poverty suggests the possibility that 
the variable of poverty was not appropriately captured in the study.   
Third, the study was limited by the application of a cross-sectional rather than a 
longitudinal study design. In a cross-sectional design, data are all collected at the same 
time, and the temporal relationship between different variables cannot be studied. The 
limitations of a cross-sectional design apply to the design of the study, in the sense that 
the independent variable of the study, poverty status, might have changed over time in a 
manner that cannot be captured in cross-sectional statistical research. For example, it is 
possible that people who were not poor were diagnosed with, and prescribed medicines 
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for, HCV; later, when contributing data to NHANES, these people might have become 
poor.  
One of the tacit assumptions of the cross-sectional design of the study was that 
poverty status was unchanged; thus, it was assumed that someone who was both poor and 
diagnosed with HCV was poor at the time of HCV diagnosis. As noted above, it is 
conceptually possible that an individual’s poverty status can change at several points 
during the cycle, introducing the possibility of a systematic error in the relationship 
between poverty and HCV diagnosis or HCV medication prescription.  In a longitudinal 
approach, there might have been a way of segmenting the sample based on poverty status 
at the time of HCV diagnosis or at the time of being prescribed HCV medication. Such an 
approach would have added to the internal validity of the findings.  
A fourth limitation of the study was that of secondary rather than primary data 
analysis.  The current study was carried out on secondary data, that is, data that had 
already been collected, tabulated, and interpreted by NHANES. One limitation of not 
having carried out primary research is that the exact nonresponse rate of the study cannot 
be calculated. Because NHANES reports nonresponse rates by questionnaire, not by 
individual question, a nonresponse rate cannot be calculated on the basis of the specific 
NHANES questions that were interpreted in this study. Another limitation of secondary 
data analysis is that of variable selection. The NHANES questionnaire contained a set list 
of questions, which were not necessarily designed for the specific purpose of measuring 
the relationship between poverty and HCV diagnosis or the prescription of HCV 
medication. In this context, one of the advantages of primary data collection might have 
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been the ability to specify questions about, and collect data pertaining to, specific aspects 
of the relationship between poverty and HCV that were not necessarily captured in the 
NHANES questions. NHANES is an epidemiological dataset that does not necessarily 
include all of the questions of interest in assessing the possible relationship between 
poverty and HCV.  
Recommendations 
The finding that poor people are essentially no different from nonpoor people in 
terms of their likelihood of having been diagnosed with HCV or having been prescribed 
medications for HCV.  In this case, the parity found between poor and nonpoor people 
suggests the possibility that public health authorities might be addressing the needs of 
this population through expedients such as mobile health clinics, free clinics, and other 
means of testing and diagnosis.  Because HCV is detrimental to public health, public 
health authorities ought to continue to undertake, and even intensify, actions designed to 
diagnose and treat poor people with HCV.   
Based on the results of this study, it is strongly recommended that larger samples 
be drawn when conducting future studies.  Even though the overall NHANES sample is 
large (nearly 10,000 individuals in the case of 2015-2016 dataset that furnished the data 
source for this study), relatively few individuals within the dataset were either diagnosed 
with HCV or prescribed medicines for HCV. As noted earlier in Chapter 5, small sample 
sizes make OR calculations less likely to be able to detect small or medium-sized but still 
statistically significant effects.  For this reason, future researchers would be well advised 
to draw larger samples.  Larger samples could be driven by eschewing epidemiological 
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datasets such as NHANES and choosing to purposively sample individuals who are more 
likely to have HCV.   
The second recommendation for future study can be made based on a design that 
can differentiate between PHSA- and HBM-based theories of poverty, HCV diagnosis, 
and HCV prescription.  As noted earlier in the chapter, both PHSA and HBM can help to 
explain why poor individuals are just as likely as nonpoor individuals to be diagnosed 
with HCV and be prescribed HCV medications.  The PHSA could explain this scenario 
by suggesting that public authorities are responsible for better service provision to the 
poor, whereas the HBM suggests that the poor themselves might be more diligent about 
seeking care.  One means of isolating the respective impact of PHSA and HBM on HCV 
diagnosis and prescription is by asking poor people who have been diagnosed with HCV, 
and who have received HCV prescriptions, about the circumstances involved in diagnosis 
and prescription. The HBM could be formally explored by means of the HBM 
questionnaires, which measure the influence of health beliefs over participants’ decisions 
to obtain diagnosis or treatment for HCV.  The relative influence of the PHSA could be 
explored by questionnaires measuring the exposure of individual subjects to mobile 
health clinics, free clinics, and other public health initiatives.  An OR model of the kind 
used in this study could be applied to these data to determine whether health beliefs were 
more predictive than exposure to public health initiatives in terms of (a) being diagnosed 
with HCV, and (b) having been prescribed HCV medications.  After applying this 
quantitative approach, future researchers could apply qualitative methods to explore how 
and why the health-seeking behaviors of poor people with HCV are formed. 
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In order to study health beliefs more closely, future researchers could draw on 
more specific aspects of the HBM (Hayden, 2013). Table 7 contains the elements of the 
HBM as specified by Hayden.  
Table 7 
Elements of the HBM 
HBM component Definition 
 
1. Perceived 
susceptibility 
 
An individual’s assessment of his or her chances of getting the 
disease. 
 
2. Perceived benefits An individual’s conclusion as to whether the new behavior is 
better than what he or she is already doing. 
 
3. Perceived barriers An individual’s opinion as to what will stop him or her from 
adopting the new behavior. 
 
4. Perceived 
seriousness 
 
An individual’s judgment as to the severity of the disease. 
 
5. Modifying 
variables 
An individual’s personal factors that affect whether the new 
behavior is adopted.  
 
6. Cues to action Those factors that will start a person on the way to changing 
behavior. 
 
7. Self-efficacy  Personal belief in one’s own ability to do something.  
 
Note. Table adapted from Hayden (2013, p. 35). 
Table 8 is an example of a data structure that could be adopted by future 
researchers who wish to measure the relationship between poverty, HCV diagnosis, and 
HBM Component 1, that is, an assessment of individual susceptibility to HCV. 
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Table 8 
Possible Data Model for HBM Study (Poverty Held Equal) 
Always 
poor, 
diagnosed 
with HCV 
Always 
poor, not 
diagnosed 
with HCV 
Gender  
(a & b) 
Race  
(a & b) 
Age  
(a & b) 
Difference 
in HBM 
score, 
Component 
1 (a-b) 
1 a 1 b Female  White 21-25 1 a-1 b 
2 a 2 b Male Black  36-40 2 a-2 b 
3 a 3 b Male Hispanic 41-45 3 a-3 b 
4 a 4 b Female Asian 65+ 4 a-4 b 
5 a 5 b Male Other 26-30 5 a-5 b 
6 a 6 b Female  White 21-25 6 a-6 b 
7 a 7 b Female  White 26-30 7 a-7 b 
8 a 8 b Male Black 26-30 8 a-8 b 
9 a 9 b Male  Black 31-35 9 a-9 b 
10 a 10 b Male White 31-35 10 a-10 b 
11 a 11 b Female Asian 21-25 11 a-11 b 
12 a 12 b Male White 36-40 12 a-12 b 
13 a 13 b Female  White 41-45 13 a-13 b 
14 a 14 b Female  Black 65+ 14 a-14 b 
15 a 15 b Male White 26-30 15 a-15 b 
16 a 16 b Female Black  21-25 16 a-16 b 
17 a 17 b Male Hispanic 26-30 17 a-17 b 
18 a 18 b Female  Asian 26-30 18 a-18 b 
19 a 19 b Male Other 31-35 19 a-19 b 
20 a 20 b Male White 31-35 20 a-20 b 
21 a 21 b Female White 21-25 21 a-21 b 
22 a 22 b Male Black 36-40 22 a-22 b 
23 a 23 b Female  Black 41-45 23 a-23 b 
24 a 24 b Female  White 65+ 24 a-24 b 
25 a 25 b Male Asian 26-30 25 a-25 b 
26 a 26 b Male  White 21-25 26 a-26 b 
27 a 27 b Male White 26-30 27 a-27 b 
28 a 28 b Female Black 26-30 28 a-28 b 
87 
 
29 a 29 b Male White 31-35 29 a-29 b 
30 a 30 b Female  Black  31-35 30 a-30 b 
31 a 31 b Female  Hispanic 21-25 31 a-31 b 
32 a 32 b Male Asian 36-40 32 a-32 b 
33 a 33 b Female Other 41-45 33 a-33 b 
34 a 34 b Male White 65+ 34 a-34 b 
35 a 35 b Female  White 26-30 35 a-35 b 
36 a 36 b Male Black 21-25 36 a-36 b 
37 a 37 b Male Black 26-30 37 a-37 b 
38 a 38 b Female White 26-30 38 a-38 b 
39 a 39 b Male Asian 31-35 39 a-39 b 
 
The data model represented in Table 8 would allow future researchers to apply the 
following approaches. First, n subjects could be divided and stratified into two groups of 
size n/2.  As in Table 8, the paired samples could be matched on the demographic bases 
of gender, race, and age. Subsample a could consist of people who have always been 
poor, and who were diagnosed with HCV. Subsample b could consist of people who have 
always been poor, and who have not been diagnosed with HCV. If, for poor people, 
belief in individual susceptibility to HCV has no effect on HCV diagnosis, then the 
expectation is that the t statistic generated from the last vector in Table 8 (difference in 
HBM score, component #1) would not be statistically significant. If the t statistic is not 
statistically significant, it could be concluded that the HBM does not predict HCV 
diagnosis among poor people, after controlling for variations gender, race, and age. As t 
is to be calculated as a-b, a t statistic that is negative as well as statistically significant 
would indicate that poor people not diagnosed with HCV have a greater belief in their 
individual susceptibility to HCV and might therefore be more likely to take HCV-
avoiding actions. 
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The approach modeled in Table 8 is one of many ways in which health beliefs 
could be integrated into the statistical models of future researchers. This data model can 
be modified by future researchers to isolate groups of interest. In Table 9, the comparison 
groups of interest have been changed from poor people diagnosed or not diagnosed with 
HCV to people diagnosed with HCV, with poverty status being the main differentiator 
between them. 
Table 9 
Possible Data Model for HBM Study (HCV Held Equal) 
Always 
poor, 
diagnosed 
with HCV 
Never poor 
diagnosed 
with HCV 
Gender  
(a & b) 
Race  
(a & b) 
Age  
(a & b) 
Difference in 
HBM score, 
Component 1 
(a-b) 
1 a 1 b Female  White 21-25 1 a-1 b 
2 a 2 b Male Black  36-40 2 a-2 b 
3 a 3 b Male Hispanic 41-45 3 a-3 b 
4 a 4 b Female Asian 65+ 4 a-4 b 
5 a 5 b Male Other 26-30 5 a-5 b 
6 a 6 b Female  White 21-25 6 a-6 b 
7 a 7 b Female  White 26-30 7 a-7 b 
8 a 8 b Male Black 26-30 8 a-8 b 
9 a 9 b Male  Black 31-35 9 a-9 b 
10 a 10 b Male White 31-35 10 a-10 b 
11 a 11 b Female Asian 21-25 11 a-11 b 
12 a 12 b Male White 36-40 12 a-12 b 
13 a 13 b Female  White 41-45 13 a-13 b 
14 a 14 b Female  Black 65+ 14 a-14 b 
15 a 15 b Male White 26-30 15 a-15 b 
16 a 16 b Female Black  21-25 16 a-16 b 
17 a 17 b Male Hispanic 26-30 17 a-17 b 
18 a 18 b Female  Asian 26-30 18 a-18 b 
19 a 19 b Male Other 31-35 19 a-19 b 
20 a 20 b Male White 31-35 20 a-20 b 
21 a 21 b Female White 21-25 21 a-21 b 
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22 a 22 b Male Black 36-40 22 a-22 b 
23 a 23 b Female  Black 41-45 23 a-23 b 
24 a 24 b Female  White 65+ 24 a-24 b 
25 a 25 b Male Asian 26-30 25 a-25 b 
26 a 26 b Male  White 21-25 26 a-26 b 
27 a 27 b Male White 26-30 27 a-27 b 
28 a 28 b Female Black 26-30 28 a-28 b 
29 a 29 b Male White 31-35 29 a-29 b 
30 a 30 b Female  Black  31-35 30 a-30 b 
31 a 31 b Female  Hispanic 21-25 31 a-31 b 
32 a 32 b Male Asian 36-40 32 a-32 b 
33 a 33 b Female Other 41-45 33 a-33 b 
34 a 34 b Male White 65+ 34 a-34 b 
35 a 35 b Female  White 26-30 35 a-35 b 
36 a 36 b Male Black 21-25 36 a-36 b 
37 a 37 b Male Black 26-30 37 a-37 b 
38 a 38 b Female White 26-30 38 a-38 b 
39 a 39 b Male Asian 31-35 39 a-39 b 
 
Other approaches are also possible. One such approach (see Table 10) would be to 
treat variations in health beliefs as predictors of the likelihood of being diagnosed with 
HCV; in such an OR model, poverty could function as a mediating variable.  A mediated 
logistic regression model could then be applied to determining whether a statistically 
significant relationship between health belief and HCV status exists because of poverty. 
The Sobel-Goodman test of mediation is one statistical approach that could be applied to 
this model; bootstrapping is another viable approach.  The approach modeled in Table 9 
can also be applied to the dependent variable of HCV diagnosis, as demonstrated in Table 
10.  
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Table 10 
Possible Data Model for HBM Study, Version 2 (Dependent Variable: Diagnosis) 
Subject 
# 
Poor or not 
poor? 
Gender Race 
HBM score, 
Component 1 
HCV 
diagnosis
? 
1 Poor/Not poor M / F Minority / White 1-7 No / Yes 
2 Poor/Not poor M / F Minority / White 1-7 No / Yes 
3 Poor/Not poor M / F Minority / White 1-7 No / Yes 
4 Poor/Not poor M / F Minority / White 1-7 No / Yes 
5 Poor/Not poor M / F Minority / White 1-7 No / Yes 
6 Poor/Not poor M / F Minority / White 1-7 No / Yes 
7 Poor/Not poor M / F Minority / White 1-7 No / Yes 
8 Poor/Not poor M / F Minority / White 1-7 No / Yes 
9 Poor/Not poor M / F Minority / White 1-7 No / Yes 
10 Poor/Not poor M / F Minority / White 1-7 No / Yes 
11 Poor/Not poor M / F Minority / White 1-7 No / Yes 
12 Poor/Not poor M / F Minority / White 1-7 No / Yes 
13 Poor/Not poor M / F Minority / White 1-7 No / Yes 
14 Poor/Not poor M / F Minority / White 1-7 No / Yes 
15 Poor/Not poor M / F Minority / White 1-7 No / Yes 
16 Poor/Not poor M / F Minority / White 1-7 No / Yes 
17 Poor/Not poor M / F Minority / White 1-7 No / Yes 
18 Poor/Not poor M / F Minority / White 1-7 No / Yes 
19 Poor/Not poor M / F Minority / White 1-7 No / Yes 
20 Poor/Not poor M / F Minority / White 1-7 No / Yes 
21 Poor/Not poor M / F Minority / White 1-7 No / Yes 
22 Poor/Not poor M / F Minority / White 1-7 No / Yes 
23 Poor/Not poor M / F Minority / White 1-7 No / Yes 
24 Poor/Not poor M / F Minority / White 1-7 No / Yes 
25 Poor/Not poor M / F Minority / White 1-7 No / Yes 
26 Poor/Not poor M / F Minority / White 1-7 No / Yes 
27 Poor/Not poor M / F Minority / White 1-7 No / Yes 
28 Poor/Not poor M / F Minority / White 1-7 No / Yes 
29 Poor/Not poor M / F Minority / White 1-7 No / Yes 
30 Poor/Not poor M / F Minority / White 1-7 No / Yes 
31 Poor/Not poor M / F Minority / White 1-7 No / Yes 
32 Poor/Not poor M / F Minority / White 1-7 No / Yes 
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33 Poor/Not poor M / F Minority / White 1-7 No / Yes 
34 Poor/Not poor M / F Minority / White 1-7 No / Yes 
35 Poor/Not poor M / F Minority / White 1-7 No / Yes 
36 Poor/Not poor M / F Minority / White 1-7 No / Yes 
37 Poor/Not poor M / F Minority / White 1-7 No / Yes 
38 Poor/Not poor M / F Minority / White 1-7 No / Yes 
39 Poor/Not poor M / F Minority / White 1-7 No / Yes 
 
Table 11 
Possible Data Model for HBM Study, Version 2 (Dependent Variable: Prescription) 
Subject # 
Poor or not 
poor? 
Gender Race 
HBM 
score, 
Component 
1 
HCV 
prescriptio
n? 
1 Poor/Not poor M / F M / W 1-7 No / Yes 
2 Poor/Not poor M / F M / W 1-7 No / Yes 
3 Poor/Not poor M / F M / W 1-7 No / Yes 
4 Poor/Not poor M / F M / W 1-7 No / Yes 
5 Poor/Not poor M / F M / W 1-7 No / Yes 
6 Poor/Not poor M / F M / W 1-7 No / Yes 
7 Poor/Not poor M / F M / W 1-7 No / Yes 
8 Poor/Not poor M / F M / W 1-7 No / Yes 
9 Poor/Not poor M / F M / W 1-7 No / Yes 
10 Poor/Not poor M / F M / W 1-7 No / Yes 
11 Poor/Not poor M / F M / W 1-7 No / Yes 
12 Poor/Not poor M / F M / W 1-7 No / Yes 
13 Poor/Not poor M / F M / W 1-7 No / Yes 
14 Poor/Not poor M / F M / W 1-7 No / Yes 
15 Poor/Not poor M / F M / W 1-7 No / Yes 
16 Poor/Not poor M / F M / W 1-7 No / Yes 
17 Poor/Not poor M / F M / W 1-7 No / Yes 
18 Poor/Not poor M / F M / W 1-7 No / Yes 
19 Poor/Not poor M / F M / W 1-7 No / Yes 
20 Poor/Not poor M / F M / W 1-7 No / Yes 
21 Poor/Not poor M / F M / W 1-7 No / Yes 
22 Poor/Not poor M / F M / W 1-7 No / Yes 
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23 Poor/Not poor M / F M / W 1-7 No / Yes 
24 Poor/Not poor M / F M / W 1-7 No / Yes 
25 Poor/Not poor M / F M / W 1-7 No / Yes 
26 Poor/Not poor M / F M / W 1-7 No / Yes 
27 Poor/Not poor M / F M / W 1-7 No / Yes 
28 Poor/Not poor M / F M / W 1-7 No / Yes 
29 Poor/Not poor M / F M / W 1-7 No / Yes 
30 Poor/Not poor M / F M / W 1-7 No / Yes 
31 Poor/Not poor M / F M / W 1-7 No / Yes 
32 Poor/Not poor M / F M / W 1-7 No / Yes 
33 Poor/Not poor M / F M / W 1-7 No / Yes 
34 Poor/Not poor M / F M / W 1-7 No / Yes 
35 Poor/Not poor M / F M / W 1-7 No / Yes 
36 Poor/Not poor M / F M / W 1-7 No / Yes 
37 Poor/Not poor M / F M / W 1-7 No / Yes 
38 Poor/Not poor M / F M / W 1-7 No / Yes 
39 Poor/Not poor M / F M / W 1-7 No / Yes 
 
Implications 
The study implies that public health authorities are performing adequately in 
terms of diagnosing poor individuals with HCV, indicating that poverty is not necessarily 
a separate transmission risk or vector for HCV.  The study also implies that public health 
authorities are succeeding in diagnosing HCV equitably, regardless of the poverty of the 
person being tested. Collectively, these implications suggest that public health is 
achieving social justice as well as diagnostic and prescriptive efficiency in dealing with 
poor people with HCV.  
Positive Social Change Implications 
The first positive social change implications of the study lies in calling attention 
to the possible relationships between poverty and disease status.  In this context, the 
contribution of the study is not based on having found a statistically significant 
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relationship between poverty and HCV, but in having modeled an approach to 
understanding the relationship between poverty and HCV, in a manner that can positively 
influence future public health analyses and thereby strengthen the social justice aspects of 
public health and policy. 
One of the foundations of positive social change is that of placing an item on an 
agenda for further consideration and analysis.  Indeed, both in terms of health policy and 
general policy, some scholars have suggested that social change tends to take place in 
three phases, each of which is related to the concept of a change agenda. First, a problem 
is not acknowledged or identified as a problem; in this stage, the problem does not exist 
on agendas and therefore cannot guide change. Second, a problem is acknowledged and 
placed on an agenda. At this stage, there can be disagreement about the precise nature of 
the problem as well as disagreement about the severity of the problem. Nevertheless, at 
this second stage, the problem exists on an agenda and can therefore inform change. In 
the third and final stage, a problem is sufficiently prominent and recognized on an agenda 
as to inform an actual change process. 
The study of the relationship between poverty and HCV could have informed 
positive social change by calling attention to a deficiency in actual public health policy 
and practice.  If, for example, there had been a statistically significant relationship 
between HCV and diagnosis, such that the likelihood of HCV diagnosis was lower for 
poor people, one possible positive social change implication could have been the 
identification of a specific weakness in how the poor are screened for HCV (assuming 
that HCV is equally distributed regardless of socioeconomic status).  
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If the likelihood of HCV diagnosis was higher for poor people, one possible 
positive social change implication could have been the identification of a specific need to 
protect the poor from HCV, for example, through more effective public health 
campaigns.  In the absence of statistically significant findings, the main positive social 
change implication of the study is contributing to the existing body of studies indicating 
that poverty (and other measures of socioeconomic status) should be taken into 
consideration when designing public health policies and practices. Therefore, although 
the absence of statistically significant findings meant that the study could not make a 
specific contribution to changes in public health policy, the study itself made a 
contribution to the objective of further entrenching poverty and socioeconomic status on 
public health agendas.  
The reason that poverty should be further entrenched on public health agendas is 
that positive change based on health policy has often been denied to the poor. 
Historically, the distribution of health is unequal in a manner that privileges the wealthy, 
who have superior access to healthcare, more access to healthcare education, and other 
tangible and intangible advantages related to the pursuit and maintenance of health. 
Given the role of economic privilege in determining levels of health, any attempt to 
further entrench poverty in public health agendas carries the possibility of positive social 
change insofar as an accumulation of research could convince public health authorities, 
and the public in general, to act more effectively to protect the health of the poor.    
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Conclusion 
The main expectations of this study were that the poor would be more likely to 
have HCV, and less likely to have been prescribed medications for it.  The failure to meet 
these expectations suggests that public authorities are performing adequately as to the 
tasks of screening for, and treating, HCV among the poor.  Therefore, public authorities 
should continue to receive public funding as well as private consideration for successfully 
achieving both socio-medical justice for the poor and impeding the transmission of HCV.  
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Appendix A: Raw Data, Individuals With HCV 
Subject  Diagnosis Prescribed? Poverty Gender Race Education Insurance Medicaid 
         
92373 HCV positive  No Female White Some College / AA Insured No Medicaid 
90223 HCV positive No No Female Black  Insured Medicaid 
87995 HCV positive No Yes Male Other Hispanic  Insured Medicaid 
         
85710 HCV positive No No Female Black HS Graduate Insured No Medicaid 
90775 HCV positive  No Female Black College or Above Insured No Medicaid 
91722 HCV positive No No Male Asian College or Above Insured No Medicaid 
92614 HCV positive Prescribed No Male Black  Insured Medicaid 
91478 HCV positive No No Male White  Insured Medicaid 
92298 HCV positive No No Female White College or Above Insured No Medicaid 
92283 HCV positive No No Female White  Insured No Medicaid 
92824 HCV positive Prescribed No Female White HS Graduate Insured No Medicaid 
88775 HCV positive No No Male Asian < 9th Grade Insured No Medicaid 
88804 HCV positive Prescribed No Female Other Hispanic  Insured No Medicaid 
90449 HCV positive No Yes Male White College or Above Not Insured No Medicaid 
92814 HCV positive No No Male Other  Insured Medicaid 
87260 HCV positive Prescribed No Male White College or Above Insured No Medicaid 
87783 HCV positive No No Male White HS Graduate Insured No Medicaid 
87891 HCV positive No No Male Mexican < 9th Grade Not Insured No Medicaid 
85215 HCV positive Prescribed No Female Black College or Above Insured No Medicaid 
91732 HCV positive No No Male Black Some College / AA Not Insured No Medicaid 
93568 HCV positive Prescribed Yes Female Other Some College / AA Not Insured No Medicaid 
91341 HCV positive No No Female Black Some College / AA Insured No Medicaid 
85028 HCV positive No No Female White College or Above Insured No Medicaid 
83827 HCV positive Prescribed No Female Mexican  Not Insured No Medicaid 
89208 HCV positive Prescribed Yes Male Other Hispanic College or Above Not Insured No Medicaid 
87916 HCV positive No No Male Other  Not Insured No Medicaid 
87750 HCV positive No No Female Mexican  Insured No Medicaid 
86094 HCV positive No No Male Other Hispanic Some College / AA Insured No Medicaid 
93449 HCV positive Prescribed Yes Female Mexican  Insured Medicaid 
83884 HCV positive No No Male White Some College / AA Insured No Medicaid 
89967 HCV positive  No Female Other Hispanic College or Above Insured No Medicaid 
93522 HCV positive No No Male White Some College / AA Insured No Medicaid 
92243 HCV positive Prescribed No Female Mexican  Insured No Medicaid 
90447 HCV positive Prescribed Yes Male Black  Insured Medicaid 
90034 HCV positive No No Male Asian 9-11 Grade Insured No Medicaid 
90200 HCV positive Prescribed No Female Other Hispanic Some College / AA Not Insured No Medicaid 
89806 HCV positive No No Male Mexican College or Above Insured No Medicaid 
85648 HCV positive No No Female Black Some College / AA Insured No Medicaid 
84225 HCV positive Prescribed No Female Other Hispanic  Insured No Medicaid 
87818 HCV positive  Yes Male White HS Graduate Not Insured No Medicaid 
91965 HCV positive No Yes Female Black  Insured Medicaid 
89351 HCV positive Prescribed No Male Mexican 9-11 Grade Not Insured No Medicaid 
89538 HCV positive No Yes Male Asian  Insured No Medicaid 
91600 HCV positive No No Female White Some College / AA Insured No Medicaid 
91793 HCV positive No No Male Other Hispanic  Insured Medicaid 
91343 HCV positive No No Male White Some College / AA Insured No Medicaid 
84785 HCV positive No Yes Female Mexican  Not Insured No Medicaid 
91924 HCV positive No Yes Male Black HS Graduate Not Insured No Medicaid 
90480 HCV positive No No Female White Some College / AA Insured No Medicaid 
90131 HCV positive No No Female White College or Above Insured No Medicaid 
83845 HCV positive No Yes Female Mexican < 9th Grade Not Insured No Medicaid 
92472 HCV positive  Yes Female Asian Some College / AA Insured Medicaid 
90367 HCV positive Prescribed Yes Male Black  Insured Medicaid 
87064 HCV positive  No Female Mexican  Insured Medicaid 
91455 HCV positive No Yes Male Other  Insured Medicaid 
84111 HCV positive No No Male Mexican  Insured No Medicaid 
90671 HCV positive  Yes Male Mexican Some College / AA Insured Medicaid 
87736 HCV positive No No Male Black HS Graduate Insured No Medicaid 
90204 HCV positive Prescribed Yes Male Black  Insured Medicaid 
90303 HCV positive Prescribed No Female Black  Insured Medicaid 
93168 HCV positive No No Female Asian Some College / AA Not Insured No Medicaid 
93068 HCV positive No Yes Female Black Some College / AA Insured No Medicaid 
86809 HCV positive Prescribed Yes Male White  Not Insured No Medicaid 
91018 HCV positive  No Female Mexican < 9th Grade Insured Medicaid 
89518 HCV positive No No Female Black Some College / AA Insured No Medicaid 
91886 HCV positive Prescribed No Female Mexican HS Graduate Not Insured No Medicaid 
84267 HCV positive No No Female White  Insured No Medicaid 
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84309 HCV positive Prescribed No Female Black  Insured No Medicaid 
93454 HCV positive Prescribed No Male Black Some College / AA Insured No Medicaid 
92312 HCV positive No No Female Other Hispanic HS Graduate Insured Medicaid 
86052 HCV positive No No Male Mexican  Insured No Medicaid 
89107 HCV positive No No Male White Some College / AA Insured No Medicaid 
86319 HCV positive No No Male White Some College / AA Insured No Medicaid 
85790 HCV positive No No Female Black 9-11 Grade Insured No Medicaid 
85803 HCV positive No No Female Mexican 9-11 Grade Insured Medicaid 
91681 HCV positive Prescribed No Male Other Hispanic HS Graduate Not Insured No Medicaid 
83894 HCV positive No Yes Male Black  Insured Medicaid 
87605 HCV positive  No Female White Some College / AA Insured No Medicaid 
         
         
 
